**Antiphospholipid Antibodies Syndrome and Reproductive Failures: New Therapeutic Trends Beyond Aspirin and Heparin**

Chiara Tersigni, Silvia D'Ippolito and Nicoletta Di Simone

Additional information is available at the end of the chapter

http://dx.doi.org/10.5772/56862

## **1. Introduction**

The most investigated thrombophilia related to obstetrical complications is the antiphospho‐ lipid antibodies syndrome (APS), also known as Hughes' syndrome. APS is characterized by recurrent thrombosis (arterial or venous, or both) and/or morbidity during pregnancy (losses during early and late pregnancy and pre-eclampsia) associated with moderate to high plasma levels of antiphospholipid (aPL) antibodies (anticardiolipin antibodies, antibodies to β2 glycoprotein I [β2GPI] or lupus anticoagulants) [1-2].

According to the last International consensus statement for APS diagnostic criteria, in order to make diagnosis of the syndrome, the combination of at least one clinical and one laboratory criterion is required [2] (Table 1).

Since aPL antibodies have thrombogenic properties, intraplacental thrombosis with maternal– fetal blood exchange impairment was traditionally suggested to be the main pathogenic mechanism responsible of fetal loss in patients with APS, providing the rationale for the use of aspirin or heparin to prevent adverse pregnancy outcomes in APS [3-5].

Although the management of aPL antibodies-positive pregnant patients is controversial due to the limited well-designed controlled trials, the current recommendation is to use low-dose aspirin and prophylactic or therapeutic doses of heparin for patients fulfilling the updated Sapporo APS classification criteria [2] and no treatment for asymptomatic (no history of pregnancy complications and/or thrombosis) persistently aPL antibodies-positive patients [6].


recurrent miscarriage, defined as the occurrence of three or more unexplained consecutive miscarriages before the 10th week of gestation. Other obstetric features of APS are unexplained fetal deaths, occurring at or beyond the 10th week of gestation, and premature births of a morphologically healthy newborn baby before the 34th week of gestation because of eclampsia

Antiphospholipid Antibodies Syndrome and Reproductive Failures: New Therapeutic Trends Beyond…

http://dx.doi.org/10.5772/56862

85

Recurrentmiscarriage occurs inabout 1% ofthe generalpopulationattempting tohave children [11] and about 10–15% of women with recurrent miscarriage are diagnosed with APS [12,13]. Fetal death in the second or third trimesters of pregnancy occurs in up to 5% of unselected pregnancies [14] but it is less likely as pregnancy advances [15]. Although fetal death occurs significantly most often in APS [16], the overall contribution of this syndrome to its pathogene‐ sis is unknown, because of the effect of other possible contributing factors such as underlying hypertension or pre-existing comorbidities, like systemic lupus erythematosus (SLE) or renal diseases. Furthermore, it has been observed that pregnant women with diagnosis of APS are at

Even if it is still unknown the precise relationship between aPL antibodies and the occurrence of obstetric complications, aPL antibodies seem to be detectable in 11–29% of women with preeclampsia, compared with 7% or less in controls and in 25% of women delivering growth restricted fetuses [17]. Furthermore, results from prospective cohort studies indicate that among pregnant women with high concentrations of aPL antibodies, 10–50% develop preeclampsia, and more than 10% of these women deliver infants who are

A significant correlation between aPL positivity and increased risk of fetal loss has also been established. In particular, the strongest association has been observed with ACA positivity, followed by annexin V, lupus anticoagulant and anti-β2GPI. In addition, lupus anticoagulant seems to be significantly associated with early pregnancy loss compared to

**3. Pathogenetic mechanisms mediated by aPL antibodies and related**

The molecular mechanisms underlying thrombosis and fetal death in APS have long been investigated. The main target antigens reported in patients with APS include β2GPI/cardioli‐ pin, prothrombin and annexin V [19]. Other putative antigens are thrombin, protein C, protein S, thrombomodulin, tissue plasminogen activator, kininogens (high or low molecular), prekallikrein, factor VII/VIIa, factor XI, factor XII, complement component C4, heparan sulfate proteoglycan, heparin, oxidised low-density lipoproteins [19,20]. The main autoantigens are attracted to negatively charged phospholipids exposed on the outer side of cell membranes in great amounts only under special circumstances such as damage or apoptosis (e.g. endothelial

increased risk for developing preeclampsia or placental insufficiency.

or severe preeclampsia [10].

small for gestational age [17].

late pregnancy loss [18]

**therapeutic approaches**

**3.1. Vascular and placental thrombosis**

cell) or after activation (e.g. platelets) [19].

**Table 1.** Revised diagnostic criteria of APS [2].

In the last years, progress has been made in characterizing the molecular basis of aPL anti‐ bodies pathogenicity, which includes direct effects on platelets, endothelial cells and mono‐ cytes as well as activation of complement. Furthermore, it has been widely shown that pregnancy loss cannot be attributed exclusively to placental thrombosis and that other pathogenic mechanisms like functional trophoblast impairment, angiogenesis inhibition or complement-mediated placental injury may occur (see more below). Based on these findings, novel therapeutic targets are currently being explored for APS in order to address the unmet needs of better, safer and ideally targeted therapy.

This chapter points to resume the known mechanisms of aPL antibodies-mediated pregnancy impairment, the proven therapies and the new therapeutic perspectives to ameliorate obstetric outcomes of pregnant women with APS.

## **2. Adverse pregnancy outcomes associated to APS**

Beyond thromboses, obstetric complications are the other main features of APS. Such associ‐ ation is supported by several epidemiological studies and experimental models showing that passive transfer of aPL IgG induces fetal losses and growth retardation in pregnant naive mice, giving the proof that aPL antibodies are involved in determining the clinical manifestations of the syndrome [7-9]. The most common adverse pregnancy outcome associated to APS is recurrent miscarriage, defined as the occurrence of three or more unexplained consecutive miscarriages before the 10th week of gestation. Other obstetric features of APS are unexplained fetal deaths, occurring at or beyond the 10th week of gestation, and premature births of a morphologically healthy newborn baby before the 34th week of gestation because of eclampsia or severe preeclampsia [10].

Recurrentmiscarriage occurs inabout 1% ofthe generalpopulationattempting tohave children [11] and about 10–15% of women with recurrent miscarriage are diagnosed with APS [12,13]. Fetal death in the second or third trimesters of pregnancy occurs in up to 5% of unselected pregnancies [14] but it is less likely as pregnancy advances [15]. Although fetal death occurs significantly most often in APS [16], the overall contribution of this syndrome to its pathogene‐ sis is unknown, because of the effect of other possible contributing factors such as underlying hypertension or pre-existing comorbidities, like systemic lupus erythematosus (SLE) or renal diseases. Furthermore, it has been observed that pregnant women with diagnosis of APS are at increased risk for developing preeclampsia or placental insufficiency.

Even if it is still unknown the precise relationship between aPL antibodies and the occurrence of obstetric complications, aPL antibodies seem to be detectable in 11–29% of women with preeclampsia, compared with 7% or less in controls and in 25% of women delivering growth restricted fetuses [17]. Furthermore, results from prospective cohort studies indicate that among pregnant women with high concentrations of aPL antibodies, 10–50% develop preeclampsia, and more than 10% of these women deliver infants who are small for gestational age [17].

A significant correlation between aPL positivity and increased risk of fetal loss has also been established. In particular, the strongest association has been observed with ACA positivity, followed by annexin V, lupus anticoagulant and anti-β2GPI. In addition, lupus anticoagulant seems to be significantly associated with early pregnancy loss compared to late pregnancy loss [18]

## **3. Pathogenetic mechanisms mediated by aPL antibodies and related therapeutic approaches**

## **3.1. Vascular and placental thrombosis**

In the last years, progress has been made in characterizing the molecular basis of aPL anti‐ bodies pathogenicity, which includes direct effects on platelets, endothelial cells and mono‐ cytes as well as activation of complement. Furthermore, it has been widely shown that pregnancy loss cannot be attributed exclusively to placental thrombosis and that other pathogenic mechanisms like functional trophoblast impairment, angiogenesis inhibition or complement-mediated placental injury may occur (see more below). Based on these findings, novel therapeutic targets are currently being explored for APS in order to address the unmet

**Clinical criteria Laboratory criteria**

• Lupus anticoagulant present in plasma, on two or more occasions at least 12 weeks apart, detected according to the guidelines of the International Society on Thrombosis and Hemostasis (Scientific Subcommittee on lupus anticoagulant/ phospholipid-

• Anticardiolipin antibody of IgG or IgM isotype, or both, in serum or plasma, present in medium or high titres (ie, "/>40 GPL or MPL, or greater than the 99th percentile) on two or more occasions, at least 12 weeks apart, measured by a standardized ELISA. • Anti-β2-gycoprotein 1 antibody of IgG or IgM isotype, or both, in serum or plasma (in titres greater than the 99th percentile), present on two or more occasions, at least 12 weeks apart, measured by a standardized ELISA, according to recommended

dependent antibodies).

procedures.

This chapter points to resume the known mechanisms of aPL antibodies-mediated pregnancy impairment, the proven therapies and the new therapeutic perspectives to ameliorate obstetric

Beyond thromboses, obstetric complications are the other main features of APS. Such associ‐ ation is supported by several epidemiological studies and experimental models showing that passive transfer of aPL IgG induces fetal losses and growth retardation in pregnant naive mice, giving the proof that aPL antibodies are involved in determining the clinical manifestations of the syndrome [7-9]. The most common adverse pregnancy outcome associated to APS is

needs of better, safer and ideally targeted therapy.

• One or more clinical episodes of arterial, venous, or small vessel thrombosis,

• One or more unexplained deaths of a morphologically healthy foetus at or beyond the 10th week of gestation, with healthy foetal morphology documented by ultrasound or by direct examination of the fetus.

• One or more premature births of a morphologically healthy newborn baby before the 34th week of gestation because of: eclampsia or severe

preeclampsia defined according to standard definitions or recognized features

• Three or more unexplained consecutive spontaneous abortions before the 10th week of gestation, with maternal anatomical or hormonal abnormalities and paternal and maternal chromosomal causes excluded. In studies of populations of patients who have more than one type of pregnancy morbidity, investigators are strongly encouraged to stratify groups of patients according

• Thrombosis should be supported by objective validated criteria—ie, unequivocal findings of appropriate imaging studies or histopathology. For histopathological support, thrombosis should be present without substantial

Pregnancy morbidity, defined by one of the following criteria:

**2. Adverse pregnancy outcomes associated to APS**

outcomes of pregnant women with APS.

Vascular thrombosis

in any tissue or organ.

of placental failure.

to one of the three criteria.

**Table 1.** Revised diagnostic criteria of APS [2].

evidence of inflammation in the vessel wall.

84 Pregnancy Thrombophilia - The Unsuspected Risk

The molecular mechanisms underlying thrombosis and fetal death in APS have long been investigated. The main target antigens reported in patients with APS include β2GPI/cardioli‐ pin, prothrombin and annexin V [19]. Other putative antigens are thrombin, protein C, protein S, thrombomodulin, tissue plasminogen activator, kininogens (high or low molecular), prekallikrein, factor VII/VIIa, factor XI, factor XII, complement component C4, heparan sulfate proteoglycan, heparin, oxidised low-density lipoproteins [19,20]. The main autoantigens are attracted to negatively charged phospholipids exposed on the outer side of cell membranes in great amounts only under special circumstances such as damage or apoptosis (e.g. endothelial cell) or after activation (e.g. platelets) [19].

Endothelial cells, activated by aPL antibodies with anti-β2GPI activity, express adhesion molecules such as intercellular cell adhesion molecule-1, vascular cell adhesion molecule-1, Eselectin, and both endothelial cells and monocytes upregulate the production of tissue factor (TF) [21]. All at once, activated platelets increase expression of glycoprotein IIb-IIIa and synthesis of thromboxane A2, determining a procoagulant state [21-25].

On the fetal side, β2GPI has been shown to be expressed on trophoblast cell membranes, explaining the placental tropism of anti-β2GPI antibodies. Being a cationic plasma protein, β2GPI has been suggested to bind to exposed phosphatidylserine on the external cell mem‐

Antiphospholipid Antibodies Syndrome and Reproductive Failures: New Therapeutic Trends Beyond…

http://dx.doi.org/10.5772/56862

87

β2GPI-dependent antibodies can adhere to human trophoblast cells in vitro [39], consistently with the hypothesis that the visibility of anionic PLs on the external cell surface during intertrophoblastic fusion might offer a useful substrate for the cation PL-binding site [40,41]. The binding to anionic structures induces the expression of new cryptic epitopes and/or increases the antigenic density, two events that are apparently pivotal for the antibody binding [42]. In vitro studies with both murine and human monoclonal antibodies, as well as with polyclonal IgG antibodies from APS patients, have clearly demonstrated a binding to troph‐ oblast monolayers [39,43]. Interestingly, antibodies obtained from patients with APS, once bound, can affect the trophoblast functions in vitro, inducing cell injury and apoptosis, inhibition of proliferation and formation of syncitia, decreased production of human chorionic gonadotrophin, defective secretion of growth factors and impaired invasiveness [39]. β2GPIdependent aPL antibodies seem, therefore, to represent the main pathogenic autoantibodies

The most important mechanism by which heparin acts protecting placenta in APS seems to be its ability to prevent the binding of aPL antibodies to trophoblast cells. Indeed, using an expression/site-directed mutagenesis approach, Guerin demonstrated that the primary heparin-binding site of β2-GPI is the positively charged site located within the fifth domain of the protein, which also binds to PL [44]. Furthermore, we demonstrated that heparin reduces the aPL antibody binding to trophoblast cells in vitro and that it is able to restore placental

Recent findings have underlined a further mechanism by which aPL antibodies binding to human trophoblast could affect its functions: the aPL antibodies-mediated reduction of placental Heparin-Binding Epidermal Growth Factor–like growth factor (HB-EGF) expression. HB-EGF is a member of the EGF family [47,48]. It has been shown to induce an invasive trophoblast phenotype in human and mouse blastocysts [49,50] and to initiate the molecular and cellular changes characteristic of decidualization in mice [51]. HB-EGF is expressed in the human placenta during the first trimester, primarily within the villous trophoblast, but also in the extravillous cytotrophoblast, predominantly at the sites of cytotrophoblast extravillous invasion [52]. Women with preeclampsia and infants small for gestational age display decreased placental expression of HB-EGF [53], strongly suggesting an association between HB-EGF down-regulation, poor trophoblast invasion, and failed physiologic transformation

Interestingly, also in placental tissues obtained from women with APS, we found reduced expression of HB-EGF [54]. Furthermore, we showed that polyclonal and monoclonal aPL antibodies bind trophoblast monolayers in vitro significantly reducing the synthesis and the secretion of HB-EGF [55]. The ability of exogenous recombinant HB-EGF to reduce the aPL antibodies mediated effects on trophoblast cells supports the hypothesis of a key pathogenic

role of this molecule in mediating APS-related adverse pregnancy outcomes.

branes of trophoblasts undergoing syncitium formation [38].

in obstetrical APS.

invasiveness and differentiation [45,46].

of the spiral arteries occurring in these disorders.

Additional mechanisms promoting clot formation could be represented by interaction of aPL antibodies with proteins implicated in clotting regulation, such as annexin A5, prothrombin, factor X, protein C and plasmin [20,21,26].

Recent results from studies in mice highlight the role of inflammation in the pathogenesis of APS, showing a central role for complement activation in determining thrombosis and fetal loss induced by aPL antibodies [27,28]. Because many individuals with high aPL antibodies titers remain asymptomatic, a "second hit" hypothesis has been proposed. It is likely that in the aPL antibodies-induced vascular procoagulant state, activation of the complement cascade might close the loop and provoke thrombosis, often in the presence of a second hit, like tobacco, inflammation, or oestrogens [26,29,30].

Starting from the observation of the intravascular aPL antibodies-mediate clot formation, initially, intraplacental thrombosis was considered the main pathogenic mechanism media‐ ting fetal loss in APS. This hypothesis of placental damage was supported by the finding of thrombosis and infarction in placentas from women with APS and by the demonstration of aPL antibodies capability to induce a procoagulant state in vitro through several mechanisms, including their ability (specifically, anti-β2GPI antibodies)todisruptthe anticoagulant annexin A5 shield on trophoblast and endothelial cell monolayers [20,31,32]. Supporting the in vitro findings, a significantly lower distribution of annexin A5 covering the intervillous surfaces was found in the placentas of aPL antibodies-positive women in comparison with normal controls [33]. These observations supported the introduction of heparin in the prevention of fetal loss in APS, preferred to oral anticoagulant therapies for its safer profile for the fetus. Indeed, it was demonstrated that heparin, at concentrations that are reached therapeutically in vivo, greatly enhanced the plasmin-mediated cleavage of β2-GPI. Considering that the cleaved forms of β2- GPI cannot bind to PL and may be cleared more rapidly from the circulation than native β2- GPI [34], interaction with heparin should greatly reduce the prothrombotic effects of anti-β2- GPI antibodies. Yet, some clinical trials confirmed heparin therapy effectiveness in improving pregnancy outcomes in APS patients [35].

Nevertheless, since recurrence of thrombotic events occurs despite the therapy and thrombosis cannot account for all of the histopathologic findings in placentae from women with APS, other mechanisms of reproductive impairment were supposed to be involved [36,37].

#### **3.2. Defective placentation**

#### *3.2.1. Trophoblast invasiveness impairment*

New aPL antibodies-mediated pathogenic mechanisms have been proposed during the last fifteen years: anti-β2GPI antibodies seem to bind directly the maternal decidua and the invading trophoblast, determining defective placentation.

On the fetal side, β2GPI has been shown to be expressed on trophoblast cell membranes, explaining the placental tropism of anti-β2GPI antibodies. Being a cationic plasma protein, β2GPI has been suggested to bind to exposed phosphatidylserine on the external cell mem‐ branes of trophoblasts undergoing syncitium formation [38].

Endothelial cells, activated by aPL antibodies with anti-β2GPI activity, express adhesion molecules such as intercellular cell adhesion molecule-1, vascular cell adhesion molecule-1, Eselectin, and both endothelial cells and monocytes upregulate the production of tissue factor (TF) [21]. All at once, activated platelets increase expression of glycoprotein IIb-IIIa and

Additional mechanisms promoting clot formation could be represented by interaction of aPL antibodies with proteins implicated in clotting regulation, such as annexin A5, prothrombin,

Recent results from studies in mice highlight the role of inflammation in the pathogenesis of APS, showing a central role for complement activation in determining thrombosis and fetal loss induced by aPL antibodies [27,28]. Because many individuals with high aPL antibodies titers remain asymptomatic, a "second hit" hypothesis has been proposed. It is likely that in the aPL antibodies-induced vascular procoagulant state, activation of the complement cascade might close the loop and provoke thrombosis, often in the presence of a second hit, like tobacco,

Starting from the observation of the intravascular aPL antibodies-mediate clot formation, initially, intraplacental thrombosis was considered the main pathogenic mechanism media‐ ting fetal loss in APS. This hypothesis of placental damage was supported by the finding of thrombosis and infarction in placentas from women with APS and by the demonstration of aPL antibodies capability to induce a procoagulant state in vitro through several mechanisms, including their ability (specifically, anti-β2GPI antibodies)todisruptthe anticoagulant annexin A5 shield on trophoblast and endothelial cell monolayers [20,31,32]. Supporting the in vitro findings, a significantly lower distribution of annexin A5 covering the intervillous surfaces was found in the placentas of aPL antibodies-positive women in comparison with normal controls [33]. These observations supported the introduction of heparin in the prevention of fetal loss in APS, preferred to oral anticoagulant therapies for its safer profile for the fetus. Indeed, it was demonstrated that heparin, at concentrations that are reached therapeutically in vivo, greatly enhanced the plasmin-mediated cleavage of β2-GPI. Considering that the cleaved forms of β2- GPI cannot bind to PL and may be cleared more rapidly from the circulation than native β2- GPI [34], interaction with heparin should greatly reduce the prothrombotic effects of anti-β2- GPI antibodies. Yet, some clinical trials confirmed heparin therapy effectiveness in improving

Nevertheless, since recurrence of thrombotic events occurs despite the therapy and thrombosis cannot account for all of the histopathologic findings in placentae from women with APS, other

New aPL antibodies-mediated pathogenic mechanisms have been proposed during the last fifteen years: anti-β2GPI antibodies seem to bind directly the maternal decidua and the

mechanisms of reproductive impairment were supposed to be involved [36,37].

synthesis of thromboxane A2, determining a procoagulant state [21-25].

factor X, protein C and plasmin [20,21,26].

86 Pregnancy Thrombophilia - The Unsuspected Risk

inflammation, or oestrogens [26,29,30].

pregnancy outcomes in APS patients [35].

*3.2.1. Trophoblast invasiveness impairment*

invading trophoblast, determining defective placentation.

**3.2. Defective placentation**

β2GPI-dependent antibodies can adhere to human trophoblast cells in vitro [39], consistently with the hypothesis that the visibility of anionic PLs on the external cell surface during intertrophoblastic fusion might offer a useful substrate for the cation PL-binding site [40,41]. The binding to anionic structures induces the expression of new cryptic epitopes and/or increases the antigenic density, two events that are apparently pivotal for the antibody binding [42]. In vitro studies with both murine and human monoclonal antibodies, as well as with polyclonal IgG antibodies from APS patients, have clearly demonstrated a binding to troph‐ oblast monolayers [39,43]. Interestingly, antibodies obtained from patients with APS, once bound, can affect the trophoblast functions in vitro, inducing cell injury and apoptosis, inhibition of proliferation and formation of syncitia, decreased production of human chorionic gonadotrophin, defective secretion of growth factors and impaired invasiveness [39]. β2GPIdependent aPL antibodies seem, therefore, to represent the main pathogenic autoantibodies in obstetrical APS.

The most important mechanism by which heparin acts protecting placenta in APS seems to be its ability to prevent the binding of aPL antibodies to trophoblast cells. Indeed, using an expression/site-directed mutagenesis approach, Guerin demonstrated that the primary heparin-binding site of β2-GPI is the positively charged site located within the fifth domain of the protein, which also binds to PL [44]. Furthermore, we demonstrated that heparin reduces the aPL antibody binding to trophoblast cells in vitro and that it is able to restore placental invasiveness and differentiation [45,46].

Recent findings have underlined a further mechanism by which aPL antibodies binding to human trophoblast could affect its functions: the aPL antibodies-mediated reduction of placental Heparin-Binding Epidermal Growth Factor–like growth factor (HB-EGF) expression. HB-EGF is a member of the EGF family [47,48]. It has been shown to induce an invasive trophoblast phenotype in human and mouse blastocysts [49,50] and to initiate the molecular and cellular changes characteristic of decidualization in mice [51]. HB-EGF is expressed in the human placenta during the first trimester, primarily within the villous trophoblast, but also in the extravillous cytotrophoblast, predominantly at the sites of cytotrophoblast extravillous invasion [52]. Women with preeclampsia and infants small for gestational age display decreased placental expression of HB-EGF [53], strongly suggesting an association between HB-EGF down-regulation, poor trophoblast invasion, and failed physiologic transformation of the spiral arteries occurring in these disorders.

Interestingly, also in placental tissues obtained from women with APS, we found reduced expression of HB-EGF [54]. Furthermore, we showed that polyclonal and monoclonal aPL antibodies bind trophoblast monolayers in vitro significantly reducing the synthesis and the secretion of HB-EGF [55]. The ability of exogenous recombinant HB-EGF to reduce the aPL antibodies mediated effects on trophoblast cells supports the hypothesis of a key pathogenic role of this molecule in mediating APS-related adverse pregnancy outcomes.

We also observed that the addition of heparin inhibited aPL antibodies binding and restored HB-EGF expression in a dose-dependent manner [54]. These findings suggest that the reduc‐ tion of aPL antibodies-mediated HB-EGF represents an additional mechanism that is respon‐ sible for the defective placentation associated with APS and provide one more proof that heparin works in protecting pregnancy from aPL antibodies-induced damage by inhibiting antibody binding to trophoblast cells.

expression and the recognition by specific autoantibodies [59,60]. It has been shown that a twenty amino acid synthetic peptide of viral origin spanning Thr101-Thr120 of ULB0-HCMVA from human Cytomegalovirus (TIFI) shares similarity with a 15 amino acid sequence rich in lysines in the Vth domain of β2GPI located in the PL-binding site [61]. TIFI inhibits the binding of FITC-conjugated β2GPI to human endothelial cells and murine monocytes in vitro. It has been demonstrated that this peptide is not recognized by aPL antibodies but it is able to reverse the aPL antibodies-mediated thrombosis in mice [59]. Furthermore, TIFI was recently shown to inhibit also the binding of monoclonal human β2GPI-dependent aPL antibodies to human trophoblast in vitro, and, more importantly, it has been observed that repeated injections of TIFI protected pregnant naïve mice from fetal loss and growth retardation induced by passive infusion of human aPL IgG [62-64]. Since β2GPI was shown to bind endothelial cells and trophoblasts through the PL-binding site, it has been suggested that TIFI might compete with β2GPI in the binding to cell membranes so reducing the amount of the target antigen available for aPL antibodies and ultimately might reverse the autoantibody-mediated pro-thrombotic

Antiphospholipid Antibodies Syndrome and Reproductive Failures: New Therapeutic Trends Beyond…

http://dx.doi.org/10.5772/56862

89

**Figure 1.** TIFI competes with β2GPI in the binding to HEEC membranes reducing the amount of the target antigen available for

TIFI aPL

Endometrial Endothelial cells

**Figure 1.** TIFI competes with β2GPI in the binding to HEEC membranes reducing the amount of the target antigen

Based on these recent discoveries, we examined the ability of TIFI to interfere with aPL antibodies-mediated inhibition of human endometrial angiogenesis and we observed that the peptide is able to revert the anti-angiogenic effects mediated by a β2GPI-dependent aPL monoclonal IgG on HEEC both in vitro and in vivo [66]. We showed for the first time that TIFI is able to prevent the effects of β2GPI-dependent aPL antibodies on human endometrial endothelial cell (HEEC) functions. In fact, the addition of TIFI to HEEC cultures restores VEGF expression and MMP-2 gelatinolytic capacity affected by β2GPI-dependent monoclonal aPL antibodies [66]. This finding is also confirmed by parallel experiments performed in a murine

a P L

A physiological pregnancy development requires a fine regulation of the maternal immune response during embryo implantation. Acute inflammatory events are recognized causes of adverse pregnancy outcomes, and proinflammatory mediators, such as complement, tumor necrosis factor (TNF), and CC chemokines, have been shown to play a role in animal models of aPL

Recently, the excessive activation of complement system at the fetal-maternal interface has been proposed as an additional aPL antibodies-mediated mechanism of placental damage responsible for negative outcome in APS. In pregnant murine model of APS, Girardi et al. demonstrated that aPL antibodies, preferentially targeted at deciduas and placentas, activate the complement system through the classical pathway, leading to generation of potent anaphylatoxins and mediators of effector-cell activation. The recruitment of inflammatory cells accelerates local alternative pathway activation and creates a proinflammatory amplification loop that enhances complement component 3 (C3) activation and deposition, generates additional C3a and C5a and results in further

The pathogenic mechanism of complement-mediated fetal loss induced by aPL antibodies is also supported by the protection that deficiency in complement components confers on the animals, or that follows from in vivo inhibition of complement [68,69]. Hence,

Interestingly, Girardi and co-workers demonstrated that treatment with heparin prevent complement activation in vivo and protect mice from pregnancy complications induced by aPL antibodies [28]. Such low doses of heparin, lacking anticoagulant effects, inhibited inflammatory responses at the level of leukocyte adhesion and influx and limited tissue injury [70-73] Neither fondaparinux nor hirudin, other anticoagulants without known effects on complement [74], prevented pregnancy loss, demonstrating that

Moreover, it has been demonstrated that heparin possesses the ability to inhibit lipopolysaccharide-induced proinflammatory cytokines (tumour necrosis factor α, interleukin 6, 8 and 1β) [75], involved in recurrent fetal loss of a murine model of APS [76]. Administration of intravenous immunoglobulin (IVIG) has been proposed as a possible treatment to prevent pregnancy loss in APS. IVIG may act by modulating the effect of cytokines as well as by inhibiting the action of pathological antibodies by either the interaction of the Fc portion of immunoglobulin with Fc receptors or the Fab receptors, or by passively acting as anti-idiotypic. IVIG also modulates the activation and effector functions of B and T lymphocytes, neutralizes pathogenic autoantibodies, and interferes with antigen presentation. Furthermore, the anti-inflammatory effect of IVIG may be due to interaction with the complement system

A physiological pregnancy development requires a fine regulation of the maternal immune response during embryo implantation. Acute inflammatory events are recognized causes of

IVIG have been shown to reduce the number of fetal resorptions in mice in which APS had been induced by immunization with aPL [78]. However, in a multicenter placebo controlled pilot study, the administration to pregnant women with APS of IVIG associated to low-dose aspirin plus heparin did not improve obstetric or neonatal outcomes beyond those achieved with a heparin and low-dose

Recently, Blank and coworkers demonstrated that anti-anti- β2GPI specific IVIG (sIVIG) are able to improve significantly the pregnancy outcome in BALB/c mice passively infused with anti-β2GPI antibodies. They also observed that incubation of sIVIG restored the anti-β2GPI antibodies-inhibited invasiveness of both JAR cells and human trophoblast cells in vitro. Based on these results, APS sIVIG may be considered as potential specific therapeutic safe compound for developing a treatment for APS patient's

Much research is still needed on the effects and proper indications for IVIG in reproductive failure. However, its prohibitive cost will probably prevent it ever becoming a first-line drug and its place is probably best reserved for severely affected patients who cannot

A new potential mechanism of aPL antibodies-mediated fetal loss linking TF and complement activation has been recently proposed. TF, best known as the primary cellular initiator of blood coagulation, also contributes to a variety of biological processes. In particular, TF is involved in inflammation and cell injury processes by interacting with protease-activated receptors (PARs) [81], a subfamily of related G protein-coupled receptors. Complexes of TF-FVIIa and TF-FVIIa-factor Xa (FXa) as well as FXa and thrombin induce pro-inflammatory signals by activating PARs and inducing the expression of TNF-α, interleukins, and adhesion

aPL antibodies and ultimately reverses the autoantibody-mediated fetal loss [66].

available for aPL antibodies and ultimately reverses the autoantibody-mediated fetal loss [66].

the complement system could be a potential therapeutic target in aPL-positive patients.

anticoagulant therapy gives insufficient protection against APS-associated miscarriage [28].

or fetal loss effects [59,61-65] (Figure 1).

**3.3 Inflammation** 

[77] .

**3.3. Inflammation**

aspirin regimen [79].

early fetal loss [80].

molecules [82–84].

be helped by simpler modes of treatment.

antibodies-induced fetal loss [67].

model of in vivo angiogenesis [66].

influx of inflammatory cells into the placenta [8].

#### *3.2.2. Endometrial angiogenesis inhibition*

On the maternal side, endometrial endothelial angiogenesis inhibition has been suggested to be a further aPL antibodies-mediated mechanism of placental damage. Indeed, aPL antibodies have been observed to selectively bind in vitro to endothelial cells isolated from human endometrium (HEEC) and to inhibit endothelial cell differentiation into capillary-like tubular structures, by reducing matrix metalloproteinase-2 (MMP-2) activity and vascular endothelial growth factor (VEGF) secretion, via a suppression of intracellular NFKB DNA binding activity [55]. Such an aPL antibodies-mediated inhibition of angiogenesis has also been confirmed in vivo in a murine model, showing a reduced angiogenesis in subcutaneous implanted angior‐ eactors in aPL antibodies-inoculated mice [55]. Since it is well known that endometrial angiogenesis and decidualization are fundamental prerequisites for successful implantation and placental development, aPL antibodies-inhibition of this central process provides an important additional mechanism able to explain the association between APS and pregnancy complications associated to placental failure, like miscarriage, fetal growth restriction and preeclampsia.

Recently, we investigated whether two low molecular weight heparins (LMWHs), tinzaparin and enoxaparin, have an effect on the aPL antibodies-inhibited endometrial angiogenesis. We demonstrated that the addition of the two LMWHs prevents aPL antibodies-mediated inhibition of HEEC angiogenesis, both in vitro and in vivo in a murine model, and that LMWHs are able to restore Nuclear Factor-κB (NF-κB) and/or STAT-3 activity, VEGF secretion and MMP-2 activity inhibited by aPL antibodies [56]. A noteworthy aspect of our results was that tinzaparin improved aPL-inhibited in vitro angiogenesis and STAT-3 activity more effectively than enoxaparin but it is difficult to explain this difference between the two LMWHs and caution is necessary in extrapolating the obtained results.

In conclusion, this study provides the demonstration of a beneficial effect of LMWHs on the aPL antibodies-inhibited HEEC angiogenesis offering a new mechanism whereby treatment with heparin protects early pregnancy in APS.

Beyond heparin administration, recently, a new therapeutic perspective has been investigated to provide a safer profile therapy to prevent aPL antibodies-mediated angiogenesis inhibition. During the last decade, several groups attempted to neutralize the pathogenic effect of aPL antibodies by using synthetic peptides reproducing the β2GPI epitopes recognized by these antibodies [57,58].

An alternative approach by other groups employed synthetic portions of the whole molecule able to compete with β2GPI in its binding to the natural cell targets, ultimately inhibiting its expression and the recognition by specific autoantibodies [59,60]. It has been shown that a twenty amino acid synthetic peptide of viral origin spanning Thr101-Thr120 of ULB0-HCMVA from human Cytomegalovirus (TIFI) shares similarity with a 15 amino acid sequence rich in lysines in the Vth domain of β2GPI located in the PL-binding site [61]. TIFI inhibits the binding of FITC-conjugated β2GPI to human endothelial cells and murine monocytes in vitro. It has been demonstrated that this peptide is not recognized by aPL antibodies but it is able to reverse the aPL antibodies-mediated thrombosis in mice [59]. Furthermore, TIFI was recently shown to inhibit also the binding of monoclonal human β2GPI-dependent aPL antibodies to human trophoblast in vitro, and, more importantly, it has been observed that repeated injections of TIFI protected pregnant naïve mice from fetal loss and growth retardation induced by passive infusion of human aPL IgG [62-64]. Since β2GPI was shown to bind endothelial cells and trophoblasts through the PL-binding site, it has been suggested that TIFI might compete with β2GPI in the binding to cell membranes so reducing the amount of the target antigen available for aPL antibodies and ultimately might reverse the autoantibody-mediated pro-thrombotic or fetal loss effects [59,61-65] (Figure 1).

**Figure 1.** TIFI competes with β2GPI in the binding to HEEC membranes reducing the amount of the target antigen available for aPL antibodies and ultimately reverses the autoantibody-mediated fetal loss [66]. **Figure 1.** TIFI competes with β2GPI in the binding to HEEC membranes reducing the amount of the target antigen available for aPL antibodies and ultimately reverses the autoantibody-mediated fetal loss [66].

**3.3 Inflammation**  A physiological pregnancy development requires a fine regulation of the maternal immune response during embryo implantation. Acute inflammatory events are recognized causes of adverse pregnancy outcomes, and proinflammatory mediators, such as complement, tumor necrosis factor (TNF), and CC chemokines, have been shown to play a role in animal models of aPL antibodies-induced fetal loss [67]. Recently, the excessive activation of complement system at the fetal-maternal interface has been proposed as an additional aPL antibodies-mediated mechanism of placental damage responsible for negative outcome in APS. In pregnant murine model of APS, Girardi et al. demonstrated that aPL antibodies, preferentially targeted at deciduas and placentas, activate the complement system through the classical pathway, leading to generation of potent anaphylatoxins and mediators of effector-cell activation. The recruitment of inflammatory cells accelerates local alternative pathway activation and creates a proinflammatory amplification loop that enhances complement component 3 (C3) activation and deposition, generates additional C3a and C5a and results in further influx of inflammatory cells into the placenta [8]. The pathogenic mechanism of complement-mediated fetal loss induced by aPL antibodies is also supported by the protection that deficiency in complement components confers on the animals, or that follows from in vivo inhibition of complement [68,69]. Hence, the complement system could be a potential therapeutic target in aPL-positive patients. Interestingly, Girardi and co-workers demonstrated that treatment with heparin prevent complement activation in vivo and protect Based on these recent discoveries, we examined the ability of TIFI to interfere with aPL antibodies-mediated inhibition of human endometrial angiogenesis and we observed that the peptide is able to revert the anti-angiogenic effects mediated by a β2GPI-dependent aPL monoclonal IgG on HEEC both in vitro and in vivo [66]. We showed for the first time that TIFI is able to prevent the effects of β2GPI-dependent aPL antibodies on human endometrial endothelial cell (HEEC) functions. In fact, the addition of TIFI to HEEC cultures restores VEGF expression and MMP-2 gelatinolytic capacity affected by β2GPI-dependent monoclonal aPL antibodies [66]. This finding is also confirmed by parallel experiments performed in a murine model of in vivo angiogenesis [66].

#### inhibited inflammatory responses at the level of leukocyte adhesion and influx and limited tissue injury [70-73] Neither fondaparinux nor hirudin, other anticoagulants without known effects on complement [74], prevented pregnancy loss, demonstrating that anticoagulant therapy gives insufficient protection against APS-associated miscarriage [28]. **3.3. Inflammation**

[77] .

aspirin regimen [79].

early fetal loss [80].

molecules [82–84].

be helped by simpler modes of treatment.

We also observed that the addition of heparin inhibited aPL antibodies binding and restored HB-EGF expression in a dose-dependent manner [54]. These findings suggest that the reduc‐ tion of aPL antibodies-mediated HB-EGF represents an additional mechanism that is respon‐ sible for the defective placentation associated with APS and provide one more proof that heparin works in protecting pregnancy from aPL antibodies-induced damage by inhibiting

On the maternal side, endometrial endothelial angiogenesis inhibition has been suggested to be a further aPL antibodies-mediated mechanism of placental damage. Indeed, aPL antibodies have been observed to selectively bind in vitro to endothelial cells isolated from human endometrium (HEEC) and to inhibit endothelial cell differentiation into capillary-like tubular structures, by reducing matrix metalloproteinase-2 (MMP-2) activity and vascular endothelial growth factor (VEGF) secretion, via a suppression of intracellular NFKB DNA binding activity [55]. Such an aPL antibodies-mediated inhibition of angiogenesis has also been confirmed in vivo in a murine model, showing a reduced angiogenesis in subcutaneous implanted angior‐ eactors in aPL antibodies-inoculated mice [55]. Since it is well known that endometrial angiogenesis and decidualization are fundamental prerequisites for successful implantation and placental development, aPL antibodies-inhibition of this central process provides an important additional mechanism able to explain the association between APS and pregnancy complications associated to placental failure, like miscarriage, fetal growth restriction and

Recently, we investigated whether two low molecular weight heparins (LMWHs), tinzaparin and enoxaparin, have an effect on the aPL antibodies-inhibited endometrial angiogenesis. We demonstrated that the addition of the two LMWHs prevents aPL antibodies-mediated inhibition of HEEC angiogenesis, both in vitro and in vivo in a murine model, and that LMWHs are able to restore Nuclear Factor-κB (NF-κB) and/or STAT-3 activity, VEGF secretion and MMP-2 activity inhibited by aPL antibodies [56]. A noteworthy aspect of our results was that tinzaparin improved aPL-inhibited in vitro angiogenesis and STAT-3 activity more effectively than enoxaparin but it is difficult to explain this difference between the two LMWHs and

In conclusion, this study provides the demonstration of a beneficial effect of LMWHs on the aPL antibodies-inhibited HEEC angiogenesis offering a new mechanism whereby treatment

Beyond heparin administration, recently, a new therapeutic perspective has been investigated to provide a safer profile therapy to prevent aPL antibodies-mediated angiogenesis inhibition. During the last decade, several groups attempted to neutralize the pathogenic effect of aPL antibodies by using synthetic peptides reproducing the β2GPI epitopes recognized by these

An alternative approach by other groups employed synthetic portions of the whole molecule able to compete with β2GPI in its binding to the natural cell targets, ultimately inhibiting its

caution is necessary in extrapolating the obtained results.

with heparin protects early pregnancy in APS.

antibody binding to trophoblast cells.

88 Pregnancy Thrombophilia - The Unsuspected Risk

*3.2.2. Endometrial angiogenesis inhibition*

preeclampsia.

antibodies [57,58].

Moreover, it has been demonstrated that heparin possesses the ability to inhibit lipopolysaccharide-induced proinflammatory cytokines (tumour necrosis factor α, interleukin 6, 8 and 1β) [75], involved in recurrent fetal loss of a murine model of APS [76]. Administration of intravenous immunoglobulin (IVIG) has been proposed as a possible treatment to prevent pregnancy loss in APS. A physiological pregnancy development requires a fine regulation of the maternal immune response during embryo implantation. Acute inflammatory events are recognized causes of

mice from pregnancy complications induced by aPL antibodies [28]. Such low doses of heparin, lacking anticoagulant effects,

IVIG may act by modulating the effect of cytokines as well as by inhibiting the action of pathological antibodies by either the interaction of the Fc portion of immunoglobulin with Fc receptors or the Fab receptors, or by passively acting as anti-idiotypic. IVIG also modulates the activation and effector functions of B and T lymphocytes, neutralizes pathogenic autoantibodies, and interferes with antigen presentation. Furthermore, the anti-inflammatory effect of IVIG may be due to interaction with the complement system

IVIG have been shown to reduce the number of fetal resorptions in mice in which APS had been induced by immunization with aPL [78]. However, in a multicenter placebo controlled pilot study, the administration to pregnant women with APS of IVIG associated to low-dose aspirin plus heparin did not improve obstetric or neonatal outcomes beyond those achieved with a heparin and low-dose

Recently, Blank and coworkers demonstrated that anti-anti- β2GPI specific IVIG (sIVIG) are able to improve significantly the pregnancy outcome in BALB/c mice passively infused with anti-β2GPI antibodies. They also observed that incubation of sIVIG restored the anti-β2GPI antibodies-inhibited invasiveness of both JAR cells and human trophoblast cells in vitro. Based on these results, APS sIVIG may be considered as potential specific therapeutic safe compound for developing a treatment for APS patient's

Much research is still needed on the effects and proper indications for IVIG in reproductive failure. However, its prohibitive cost will probably prevent it ever becoming a first-line drug and its place is probably best reserved for severely affected patients who cannot

A new potential mechanism of aPL antibodies-mediated fetal loss linking TF and complement activation has been recently proposed. TF, best known as the primary cellular initiator of blood coagulation, also contributes to a variety of biological processes. In particular, TF is involved in inflammation and cell injury processes by interacting with protease-activated receptors (PARs) [81], a subfamily of related G protein-coupled receptors. Complexes of TF-FVIIa and TF-FVIIa-factor Xa (FXa) as well as FXa and thrombin induce pro-inflammatory signals by activating PARs and inducing the expression of TNF-α, interleukins, and adhesion adverse pregnancy outcomes, and proinflammatory mediators, such as complement, tumor necrosis factor (TNF), and CC chemokines, have been shown to play a role in animal models of aPL antibodies-induced fetal loss [67].

anti-β2GPI antibodies. They also observed that incubation of sIVIG restored the anti-β2GPI antibodies-inhibited invasiveness of both JAR cells and human trophoblast cells in vitro. Based on these results, APS sIVIG may be considered as potential specific therapeutic safe compound

Antiphospholipid Antibodies Syndrome and Reproductive Failures: New Therapeutic Trends Beyond…

http://dx.doi.org/10.5772/56862

91

Much research is still needed on the effects and proper indications for IVIG in reproductive failure. However, its prohibitive cost will probably prevent it ever becoming a first-line drug and its place is probably best reserved for severely affected patients who cannot be helped by

A new potential mechanism of aPL antibodies-mediated fetal loss linking TF and complement activation has been recently proposed. TF, best known as the primary cellular initiator of blood coagulation, also contributes to a variety of biological processes. In particular, TF is involved in inflammation and cell injury processes by interacting with protease-activated receptors (PARs) [81], a subfamily of related G protein-coupled receptors. Complexes of TF-FVIIa and TF-FVIIa-factor Xa (FXa) as well as FXa and thrombin induce pro-inflammatory signals by activating PARs and inducing the expression of TNF-α, interleukins, and adhesion molecules

Increased expression of TF on monocytes from patients with APS has been reported [85–87] and in vitro studies support a direct role for aPL antibodies in inducing monocyte TF expres‐ sion. Indeed, incubation of normal monocytes with IgG from patients with APS or monoclonal aPL antibodies has been shown to induce TF expression and activity in these cells [88–90]. In particular, anti-β2GPI human monoclonal antibodies derived from APS patients enhance monocyte TF mRNA and activity in a β2GPI-dependent fashion [91]. Similarly, aPL antibodies (and specifically anti-β2GPI antibodies) have been shown to induce TF, along with inflamma‐

Ritis et al. reported that complement activation is a fundamental process in determining aPLinduced increase of TF expression on neutrophils. Indeed, in this study the authors showed that complement component C5a induced TF synthesis and expression on neutrophils through

Based on this finding, Redecha et al. investigated whether TF contributes to aPL antibodiesinduced fetal loss in mice and observed that mice treated with aPL antibodies showed strong TF staining throughout the decidua and on embryonic debris [96]. Surprisingly, neither increase in fibrin staining nor thrombi was associated with increased TF staining in deciduas from aPL antibodies-treated mice [96]. Moreover, anticoagulation with hirudin and fondaparinux was not sufficient to prevent pregnancy loss in this model. Neither TF increase nor fetal death was observed in mice deficient in complement component C5a receptor (C5aR) treated with aPL antibodies, demonstrating the importance of C5a-C5aR interac‐ tion in TF expression and fetal death in this model of APS. To assess the importance of TF in aPL antibodies-induced fetal injury, Redecha et al. inhibited TF with a monoclonal antimTF antibody 1H1 [96]. TF blockade prevented fetal death in aPL antibodies-treated mice also diminishing complement component C3 deposition and neutrophil infiltration in

for developing a treatment for APS patient's early fetal loss [80].

tory cytokines and adhesion molecules, on endothelial cells [92–94].

simpler modes of treatment.

interaction with C5a receptor [95].

deciduas [96].

[82–84].

Recently, the excessive activation of complement system at the fetal-maternal interface has been proposed as an additional aPL antibodies-mediated mechanism of placental damage responsible for negative outcome in APS. In pregnant murine model of APS, Girardi et al. demonstrated that aPL antibodies, preferentially targeted at deciduas and placentas, activate the complement system through the classical pathway, leading to generation of potent anaphylatoxins and mediators of effector-cell activation. The recruitment of inflammatory cells accelerates local alternative pathway activation and creates a proinflammatory amplification loop that enhances complement component 3 (C3) activation and deposition, generates additional C3a and C5a and results in further influx of inflammatory cells into the placenta [8].

The pathogenic mechanism of complement-mediated fetal loss induced by aPL antibodies is also supported by the protection that deficiency in complement components confers on the animals, or that follows from in vivo inhibition of complement [68,69]. Hence, the complement system could be a potential therapeutic target in aPL-positive patients.

Interestingly, Girardi and co-workers demonstrated that treatment with heparin prevent complement activation in vivo and protect mice from pregnancy complications induced by aPL antibodies [28]. Such low doses of heparin, lacking anticoagulant effects, inhibited inflammatory responses at the level of leukocyte adhesion and influx and limited tissue injury [70-73] Neither fondaparinux nor hirudin, other anticoagulants without known effects on complement [74], prevented pregnancy loss, demonstrating that anticoagulant therapy gives insufficient protection against APS-associated miscarriage [28].

Moreover, it has been demonstrated that heparin possesses the ability to inhibit lipopolysac‐ charide-induced proinflammatory cytokines (tumour necrosis factor α, interleukin 6, 8 and 1β) [75], involved in recurrent fetal loss of a murine model of APS [76].

Administration of intravenous immunoglobulin (IVIG) has been proposed as a possible treatment to prevent pregnancy loss in APS. IVIG may act by modulating the effect of cytokines as well as by inhibiting the action of pathological antibodies by either the interaction of the Fc portion of immunoglobulin with Fc receptors or the Fab receptors, or by passively acting as anti-idiotypic. IVIG also modulates the activation and effector functions of B and T lympho‐ cytes, neutralizes pathogenic autoantibodies, and interferes with antigen presentation. Furthermore, the anti-inflammatory effect of IVIG may be due to interaction with the com‐ plement system [77].

IVIG have been shown to reduce the number of fetal resorptions in mice in which APS had been induced by immunization with aPL [78]. However, in a multicenter placebo controlled pilot study, the administration to pregnant women with APS of IVIG associated to low-dose aspirin plus heparin did not improve obstetric or neonatal outcomes beyond those achieved with a heparin and low-dose aspirin regimen [79].

Recently, Blank and coworkers demonstrated that anti-anti- β2GPI specific IVIG (sIVIG) are able to improve significantly the pregnancy outcome in BALB/c mice passively infused with anti-β2GPI antibodies. They also observed that incubation of sIVIG restored the anti-β2GPI antibodies-inhibited invasiveness of both JAR cells and human trophoblast cells in vitro. Based on these results, APS sIVIG may be considered as potential specific therapeutic safe compound for developing a treatment for APS patient's early fetal loss [80].

adverse pregnancy outcomes, and proinflammatory mediators, such as complement, tumor necrosis factor (TNF), and CC chemokines, have been shown to play a role in animal models

Recently, the excessive activation of complement system at the fetal-maternal interface has been proposed as an additional aPL antibodies-mediated mechanism of placental damage responsible for negative outcome in APS. In pregnant murine model of APS, Girardi et al. demonstrated that aPL antibodies, preferentially targeted at deciduas and placentas, activate the complement system through the classical pathway, leading to generation of potent anaphylatoxins and mediators of effector-cell activation. The recruitment of inflammatory cells accelerates local alternative pathway activation and creates a proinflammatory amplification loop that enhances complement component 3 (C3) activation and deposition, generates additional C3a and C5a and results in further influx of inflammatory cells into the placenta [8]. The pathogenic mechanism of complement-mediated fetal loss induced by aPL antibodies is also supported by the protection that deficiency in complement components confers on the animals, or that follows from in vivo inhibition of complement [68,69]. Hence, the complement

Interestingly, Girardi and co-workers demonstrated that treatment with heparin prevent complement activation in vivo and protect mice from pregnancy complications induced by aPL antibodies [28]. Such low doses of heparin, lacking anticoagulant effects, inhibited inflammatory responses at the level of leukocyte adhesion and influx and limited tissue injury [70-73] Neither fondaparinux nor hirudin, other anticoagulants without known effects on complement [74], prevented pregnancy loss, demonstrating that anticoagulant therapy gives

Moreover, it has been demonstrated that heparin possesses the ability to inhibit lipopolysac‐ charide-induced proinflammatory cytokines (tumour necrosis factor α, interleukin 6, 8 and

Administration of intravenous immunoglobulin (IVIG) has been proposed as a possible treatment to prevent pregnancy loss in APS. IVIG may act by modulating the effect of cytokines as well as by inhibiting the action of pathological antibodies by either the interaction of the Fc portion of immunoglobulin with Fc receptors or the Fab receptors, or by passively acting as anti-idiotypic. IVIG also modulates the activation and effector functions of B and T lympho‐ cytes, neutralizes pathogenic autoantibodies, and interferes with antigen presentation. Furthermore, the anti-inflammatory effect of IVIG may be due to interaction with the com‐

IVIG have been shown to reduce the number of fetal resorptions in mice in which APS had been induced by immunization with aPL [78]. However, in a multicenter placebo controlled pilot study, the administration to pregnant women with APS of IVIG associated to low-dose aspirin plus heparin did not improve obstetric or neonatal outcomes beyond those achieved

Recently, Blank and coworkers demonstrated that anti-anti- β2GPI specific IVIG (sIVIG) are able to improve significantly the pregnancy outcome in BALB/c mice passively infused with

system could be a potential therapeutic target in aPL-positive patients.

insufficient protection against APS-associated miscarriage [28].

with a heparin and low-dose aspirin regimen [79].

plement system [77].

1β) [75], involved in recurrent fetal loss of a murine model of APS [76].

of aPL antibodies-induced fetal loss [67].

90 Pregnancy Thrombophilia - The Unsuspected Risk

Much research is still needed on the effects and proper indications for IVIG in reproductive failure. However, its prohibitive cost will probably prevent it ever becoming a first-line drug and its place is probably best reserved for severely affected patients who cannot be helped by simpler modes of treatment.

A new potential mechanism of aPL antibodies-mediated fetal loss linking TF and complement activation has been recently proposed. TF, best known as the primary cellular initiator of blood coagulation, also contributes to a variety of biological processes. In particular, TF is involved in inflammation and cell injury processes by interacting with protease-activated receptors (PARs) [81], a subfamily of related G protein-coupled receptors. Complexes of TF-FVIIa and TF-FVIIa-factor Xa (FXa) as well as FXa and thrombin induce pro-inflammatory signals by activating PARs and inducing the expression of TNF-α, interleukins, and adhesion molecules [82–84].

Increased expression of TF on monocytes from patients with APS has been reported [85–87] and in vitro studies support a direct role for aPL antibodies in inducing monocyte TF expres‐ sion. Indeed, incubation of normal monocytes with IgG from patients with APS or monoclonal aPL antibodies has been shown to induce TF expression and activity in these cells [88–90]. In particular, anti-β2GPI human monoclonal antibodies derived from APS patients enhance monocyte TF mRNA and activity in a β2GPI-dependent fashion [91]. Similarly, aPL antibodies (and specifically anti-β2GPI antibodies) have been shown to induce TF, along with inflamma‐ tory cytokines and adhesion molecules, on endothelial cells [92–94].

Ritis et al. reported that complement activation is a fundamental process in determining aPLinduced increase of TF expression on neutrophils. Indeed, in this study the authors showed that complement component C5a induced TF synthesis and expression on neutrophils through interaction with C5a receptor [95].

Based on this finding, Redecha et al. investigated whether TF contributes to aPL antibodiesinduced fetal loss in mice and observed that mice treated with aPL antibodies showed strong TF staining throughout the decidua and on embryonic debris [96]. Surprisingly, neither increase in fibrin staining nor thrombi was associated with increased TF staining in deciduas from aPL antibodies-treated mice [96]. Moreover, anticoagulation with hirudin and fondaparinux was not sufficient to prevent pregnancy loss in this model. Neither TF increase nor fetal death was observed in mice deficient in complement component C5a receptor (C5aR) treated with aPL antibodies, demonstrating the importance of C5a-C5aR interac‐ tion in TF expression and fetal death in this model of APS. To assess the importance of TF in aPL antibodies-induced fetal injury, Redecha et al. inhibited TF with a monoclonal antimTF antibody 1H1 [96]. TF blockade prevented fetal death in aPL antibodies-treated mice also diminishing complement component C3 deposition and neutrophil infiltration in deciduas [96].

Furthermore, Redecha et al. investigated the intracellular pathway of TF complementmediated activation, observing a 5-fold increase in PAR-2 mRNA expression in neutrophils of aPL antibodies-treated mice when compared to untreated mice or mice treated with control antibodies [97] as well as an increased reactive oxygen species (ROS) production and phago‐ cytosis in neutrophils from aPL antibodies-treated mice. Interestingly, neutrophils from PAR-2 deficient (PAR-2−/−) mice displayed a dramatic reduction of neutrophil activation in aPL antibodies-treated mice [97]. Also ROS production and phagocytosis were significantly reduced in neutrophils from PAR-2−/−mice treated with aPL antibodies compared with aPL antibodies-treated wild-type mice. Specific monoclonal antibody 10H10 that selectively blocks TF-VIIa signaling through PAR-2, but not antibody 5G9 that only prevents TF procoagulant activity, prevented oxidative burst and increased phagocytosis in mice treated with aPL antibodies [97]. These results are in accordance with the previous observation that anticoagu‐ lation does not rescue pregnancies in APS [43]. In addition, neutrophils from TF δCT/δCT mice that carry a mutation in the cytoplasmic domain involved in PAR-2 signaling did not show increased oxidative stress and phagocytosis in response to aPL antibodies [97]. This data reinforces the idea that TF-FVIIa signaling is required for neutrophil activation and fetal injury in APS.

placental inflammatory response via the TLR-4/MyD88 pathway, which in turn compromises trophoblast survival. Thus, the TLR-4/MyD88 pathway may provide a new therapeutic target

Mulla et al. Investigated further mechanisms characterizing the inflammatory process occurring in vitro in trophoblast cells after aPL antibodies binding. Indeed, they demonstrated that anti-β2GPI antibodies trigger an inflammatory response in trophoblast, characterized by increased secretion of IL-8, MCP-1, GRO-α and IL-1β, and that this occurs in a TLR-4/MyD88-dependent manner [102]. At high concentrations, these antibodies also induce caspase-mediated cell death. This was attenuated upon disabling of the MyD88 pathway, suggesting that anti-β2GPI-induced inflammatory mediators compromise trophoblast survival by acting in an autocrine/paracrine manner. Enhanced IL-8, GRO-α and IL-1β secretion also occurred when trophoblast were incubated with antibodies from patients with APS. Heparin attenuated the anti-β2GPI antibody-mediated cell death, and also the pro-inflammatory response, but only at high concentrations [102]. These findings demonstrate that aPL antibodies triggers a placental inflammatory response via the TLR-4/MyD88 pathway, which in turn compromises trophoblast survival. Thus, the TLR-4/MyD88 pathway may provide a new

**Figure 2.** Statins prevent C5a-induced upregulation of TF and PAR2 expression, thereby inhibiting the release of reactive oxygen species and suppressing amplification of complement activation by factors released from neutrophils.

**Figure 2.** Statins prevent C5a-induced upregulation of TF and PAR2 expression, thereby inhibiting the release of reac‐ tive oxygen species and suppressing amplification of complement activation by factors released from neutrophils.

Trophoblast cells

S T A T I N S

Oxidative damage

PAR-2

activation

http://dx.doi.org/10.5772/56862

93

STATINS

TF FVIIa

Antiphospholipid Antibodies Syndrome and Reproductive Failures: New Therapeutic Trends Beyond…

Complement activation Neutrophil

C5a C5aR

β 2 G P I

Modified from *Girardi G. et al., Journal of Reproductive Immunology 2009* [99].

Modified from *Girardi G. et al., Journal of Reproductive Immunology 2009* [99].

The possible application of statins in the prevention of aPL antibodies-related adverse pregnancy outcomes arises from their ability to suppress TF expression in various cell types [98]. Knowing that TF is a crucial mediator in aPL antibodiesinduced pregnancy loss and that statins diminish TF expression, Girardi et al. investigated whether statins could prevent pregnancy loss in aPL antibodies-treated mice and demonstrated that simvastatin and pravastatin prevented fetal loss by reducing TF and PAR-2 expression on neutrophils, thus preventing neutrophil activation [99]. aPL antibodies-dependent increase in free radical-mediated lipid peroxidation in decidual tissue was also ameliorated by treatment with statins [99] **(Figure 2)**. These results suggest that statins prevent aPL antibodies-induced neutrophil activation, thus protecting trophoblasts from oxidative damage and rescuing the fetuses. However, given that statins are not major teratogens [100,101] and considering the beneficial effects of statins in animal studies, statins should be considered as a possible treatment for women with aPL antibodies-induced pregnancy complications. Clinical trials are needed to confirm the

Heparin, associated to low dose aspirin, is considered nowadays the gold standard for the prevention of obstetric complications in pregnant women with APS. Yet, heparin therapy administered at subanticoagulant doses has improved pregnancy outcomes in some trials of APS patients [35]. Several studies have proposed different mechanisms of action able to explain the beneficial effect of heparin in preventing adverse pregnancy outcomes associated to APS

Heparin, associated to low dose aspirin, is considered nowadays the gold standard for the prevention of obstetric complications in pregnant women with APS. Yet, heparin therapy administered at subanticoagulant doses has improved pregnancy outcomes in some trials of APS patients [35]. Several studies have proposed different mechanisms of action able to explain the beneficial effect of heparin in preventing adverse pregnancy outcomes associated to APS **(Table 2)**.

7

However, in women with APS and history of obstetric failures, pregnancy complications recur

In the last years new mechanisms of aPL-mediated pregnancy impairment, like inflammation and angiogenesis inhibition, and more specific target therapies have being examined in order

to improve pregnancy outcome in APS.

therapeutic target to improve pregnancy outcome in APS.

effectiveness of its application to humans.

aPL

β2GPI

↓ aPL antibodies binding to trophoblast cells

↑ Cleavage of β2GPI

↑ Trophoblast cells invasiveness and differentiation

↓ aPL antibodies binding to trophoblast cells

in the 15% of cases despite the therapy.

**Table 2.** Heparin mediated mechanisms of placental protection from aPL antibodies.

**Table 2. Heparin mediated mechanisms of placental protection from aPL antibodies.**

**4. Conclusions**

**Conclusions**

(Table 2).

↑ Cleavage of β2GPI ↓ Complement activation ↓ Trophoblast cells apoptosis

↑ HB-EGF expression ↑Endometrial angiogenesis

The possible application of statins in the prevention of aPL antibodies-related adverse pregnancy outcomes arises from their ability to suppress TF expression in various cell types [98]. Knowing that TF is a crucial mediator in aPL antibodies-induced pregnancy loss and that statins diminish TF expression, Girardi et al. investigated whether statins could prevent pregnancy loss in aPL antibodies-treated mice and demonstrated that simvastatin and pravastatin prevented fetal loss by reducing TF and PAR-2 expression on neutrophils, thus preventing neutrophil activation [99]. aPL antibodies-dependent increase in free radicalmediated lipid peroxidation in decidual tissue was also ameliorated by treatment with statins [99] (Figure 2). These results suggest that statins prevent aPL antibodies-induced neutrophil activation, thus protecting trophoblasts from oxidative damage and rescuing the fetuses. However, given that statins are not major teratogens [100,101] and considering the beneficial effects of statins in animal studies, statins should be considered as a possible treatment for women with aPL antibodies-induced pregnancy complications. Clinical trials are needed to confirm the effectiveness of its application to humans.

Mulla et al. Investigated further mechanisms characterizing the inflammatory process occurring in vitro in trophoblast cells after aPL antibodies binding. Indeed, they demonstrated that anti-β2GPI antibodies trigger an inflammatory response in trophoblast, characterized by increased secretion of IL-8, MCP-1, GRO-α and IL-1β, and that this occurs in a TLR-4/MyD88 dependent manner [102]. At high concentrations, these antibodies also induce caspasemediated cell death. This was attenuated upon disabling of the MyD88 pathway, suggesting that anti-β2GPI-induced inflammatory mediators compromise trophoblast survival by acting in an autocrine/paracrine manner. Enhanced IL-8, GRO-α and IL-1β secretion also occurred when trophoblast were incubated with antibodies from patients with APS. Heparin attenuated the anti-β2GPI antibody-mediated cell death, and also the pro-inflammatory response, but only at high concentrations [102]. These findings demonstrate that aPL antibodies triggers a effectiveness of its application to humans. Antiphospholipid Antibodies Syndrome and Reproductive Failures: New Therapeutic Trends Beyond… http://dx.doi.org/10.5772/56862 93

The possible application of statins in the prevention of aPL antibodies-related adverse pregnancy outcomes arises from their ability to suppress TF expression in various cell types [98]. Knowing that TF is a crucial mediator in aPL antibodiesinduced pregnancy loss and that statins diminish TF expression, Girardi et al. investigated whether statins could prevent pregnancy loss in aPL antibodies-treated mice and demonstrated that simvastatin and pravastatin prevented fetal loss by reducing TF and PAR-2 expression on neutrophils, thus preventing neutrophil activation [99]. aPL antibodies-dependent increase in free radical-mediated lipid peroxidation in decidual tissue was also ameliorated by treatment with statins [99] **(Figure 2)**. These results suggest that statins prevent aPL antibodies-induced neutrophil activation, thus protecting trophoblasts from oxidative damage and rescuing the fetuses. However, given that statins are not major teratogens [100,101] and considering the beneficial effects of statins in animal studies, statins should be considered as a possible treatment for women with aPL antibodies-induced pregnancy complications. Clinical trials are needed to confirm the

**Figure 2.** Statins prevent C5a-induced upregulation of TF and PAR2 expression, thereby inhibiting the release of reactive oxygen species and suppressing amplification of complement activation by factors released from neutrophils. Modified from *Girardi G. et al., Journal of Reproductive Immunology 2009* [99]. I **Figure 2.** Statins prevent C5a-induced upregulation of TF and PAR2 expression, thereby inhibiting the release of reac‐ tive oxygen species and suppressing amplification of complement activation by factors released from neutrophils. Modified from *Girardi G. et al., Journal of Reproductive Immunology 2009* [99].

P

placental inflammatory response via the TLR-4/MyD88 pathway, which in turn compromises trophoblast survival. Thus, the TLR-4/MyD88 pathway may provide a new therapeutic target to improve pregnancy outcome in APS. Mulla et al. Investigated further mechanisms characterizing the inflammatory process occurring in vitro in trophoblast cells after aPL antibodies binding. Indeed, they demonstrated that anti-β2GPI antibodies trigger an inflammatory response in trophoblast, characterized by increased secretion of IL-8, MCP-1, GRO-α and IL-1β, and that this occurs in a TLR-4/MyD88-dependent manner [102]. At high concentrations, these antibodies also induce caspase-mediated cell death. This was attenuated upon disabling of the MyD88 pathway, suggesting that anti-β2GPI-induced inflammatory

mediators compromise trophoblast survival by acting in an autocrine/paracrine manner. Enhanced IL-8, GRO-α and IL-1β secretion also occurred when trophoblast were incubated with antibodies from patients with APS. Heparin attenuated the anti-β2GPI antibody-mediated cell death, and also the pro-inflammatory response, but only at high concentrations

#### **4. Conclusions** [102]. These findings demonstrate that aPL antibodies triggers a placental inflammatory response via the TLR-4/MyD88 pathway, which in turn compromises trophoblast survival. Thus, the TLR-4/MyD88 pathway may provide a new therapeutic target to improve pregnancy outcome in APS.

↑ Cleavage of β2GPI

Furthermore, Redecha et al. investigated the intracellular pathway of TF complementmediated activation, observing a 5-fold increase in PAR-2 mRNA expression in neutrophils of aPL antibodies-treated mice when compared to untreated mice or mice treated with control antibodies [97] as well as an increased reactive oxygen species (ROS) production and phago‐ cytosis in neutrophils from aPL antibodies-treated mice. Interestingly, neutrophils from PAR-2 deficient (PAR-2−/−) mice displayed a dramatic reduction of neutrophil activation in aPL antibodies-treated mice [97]. Also ROS production and phagocytosis were significantly reduced in neutrophils from PAR-2−/−mice treated with aPL antibodies compared with aPL antibodies-treated wild-type mice. Specific monoclonal antibody 10H10 that selectively blocks TF-VIIa signaling through PAR-2, but not antibody 5G9 that only prevents TF procoagulant activity, prevented oxidative burst and increased phagocytosis in mice treated with aPL antibodies [97]. These results are in accordance with the previous observation that anticoagu‐ lation does not rescue pregnancies in APS [43]. In addition, neutrophils from TF δCT/δCT mice that carry a mutation in the cytoplasmic domain involved in PAR-2 signaling did not show increased oxidative stress and phagocytosis in response to aPL antibodies [97]. This data reinforces the idea that TF-FVIIa signaling is required for neutrophil activation and fetal injury

The possible application of statins in the prevention of aPL antibodies-related adverse pregnancy outcomes arises from their ability to suppress TF expression in various cell types [98]. Knowing that TF is a crucial mediator in aPL antibodies-induced pregnancy loss and that statins diminish TF expression, Girardi et al. investigated whether statins could prevent pregnancy loss in aPL antibodies-treated mice and demonstrated that simvastatin and pravastatin prevented fetal loss by reducing TF and PAR-2 expression on neutrophils, thus preventing neutrophil activation [99]. aPL antibodies-dependent increase in free radicalmediated lipid peroxidation in decidual tissue was also ameliorated by treatment with statins [99] (Figure 2). These results suggest that statins prevent aPL antibodies-induced neutrophil activation, thus protecting trophoblasts from oxidative damage and rescuing the fetuses. However, given that statins are not major teratogens [100,101] and considering the beneficial effects of statins in animal studies, statins should be considered as a possible treatment for women with aPL antibodies-induced pregnancy complications. Clinical trials are needed to

Mulla et al. Investigated further mechanisms characterizing the inflammatory process occurring in vitro in trophoblast cells after aPL antibodies binding. Indeed, they demonstrated that anti-β2GPI antibodies trigger an inflammatory response in trophoblast, characterized by increased secretion of IL-8, MCP-1, GRO-α and IL-1β, and that this occurs in a TLR-4/MyD88 dependent manner [102]. At high concentrations, these antibodies also induce caspasemediated cell death. This was attenuated upon disabling of the MyD88 pathway, suggesting that anti-β2GPI-induced inflammatory mediators compromise trophoblast survival by acting in an autocrine/paracrine manner. Enhanced IL-8, GRO-α and IL-1β secretion also occurred when trophoblast were incubated with antibodies from patients with APS. Heparin attenuated the anti-β2GPI antibody-mediated cell death, and also the pro-inflammatory response, but only at high concentrations [102]. These findings demonstrate that aPL antibodies triggers a

confirm the effectiveness of its application to humans.

in APS.

92 Pregnancy Thrombophilia - The Unsuspected Risk

Heparin, associated to low dose aspirin, is considered nowadays the gold standard for the prevention of obstetric complications in pregnant women with APS. Yet, heparin therapy administered at subanticoagulant doses has improved pregnancy outcomes in some trials of APS patients [35]. Several studies have proposed different mechanisms of action able to explain the beneficial effect of heparin in preventing adverse pregnancy outcomes associated to APS (Table 2). **Conclusions** Heparin, associated to low dose aspirin, is considered nowadays the gold standard for the prevention of obstetric complications in pregnant women with APS. Yet, heparin therapy administered at subanticoagulant doses has improved pregnancy outcomes in some trials of APS patients [35]. Several studies have proposed different mechanisms of action able to explain the beneficial effect of heparin in preventing adverse pregnancy outcomes associated to APS **(Table 2)**. **Table 2. Heparin mediated mechanisms of placental protection from aPL antibodies.** ↓ aPL antibodies binding to trophoblast cells

7

↓ aPL antibodies binding to trophoblast cells ↑ Cleavage of β2GPI ↓ Complement activation ↓ Trophoblast cells apoptosis ↑ Trophoblast cells invasiveness and differentiation ↑ HB-EGF expression ↑Endometrial angiogenesis

**Table 2.** Heparin mediated mechanisms of placental protection from aPL antibodies.

However, in women with APS and history of obstetric failures, pregnancy complications recur in the 15% of cases despite the therapy.

In the last years new mechanisms of aPL-mediated pregnancy impairment, like inflammation and angiogenesis inhibition, and more specific target therapies have being examined in order to treat more selectively the aPL antibodies-induced placental damage and to ameliorate the reproductive performance of women with APS. Studies on humans are required to verify the safety profile and effectiveness of new therapies proposed.

[7] Holers V.M., Girardi G., Mo L., Guthridge J.M., Molina H., Pierangeli S.S., Espinola R., Xiaowei L.E., Mao D., Vialpando C.G. & Salmon J.E. Complement C3 activation is required for antiphospholipid antibody-induced fetal loss. J Exp Med, Vol. 195, No.

Antiphospholipid Antibodies Syndrome and Reproductive Failures: New Therapeutic Trends Beyond…

http://dx.doi.org/10.5772/56862

95

[8] Girardi G., Berman J., Redecha P., Spruce L., Thurman J.M., Kraus D., Hollmann T.J., Casali P., Caroll M.C., Wetsel R.A., Lambris J.D., Holers V.M. & Salmon JE. Comple‐ ment C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syn‐

[9] Berman J., Girardi G. & Salmon J.E. TNF-α is a critical effector and a target for thera‐ py in antiphospholipid antibody-induced pregnancy loss. J Immunol, Vol. 174, No. 1,

[10] Miyakis S., Lockshin M.D., Atsumi T., Branch D.W., Brey R.L., Cervera R., Derksen R.H., DE Groot P.G., Koike T., Meroni P.L., Reber G., Shoenfeld Y., Tincani A., Vla‐ choyiannopoulos P.G. & Krilis S.A. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb

[11] Stirrat G.M. Recurrent miscarriage I: definition and epidemiology. Lancet, Vol. 336,

[12] Rai R.S., Regan L., Clifford K., Pickering W., Dave M., Mackie I., McNally T. & Cohen H. Antiphospholipid antibodies and ß2-glycoprotein-I in 500 women with recurrent miscarriage: results of a comprehensive screening approach. Hum Reprod, Vol. 10,

[13] Yetman D.L. & Kutteh W.H. Antiphospholipid antibody panels and recurrent preg‐ nancy loss: prevalence of anticardiolipin antibodies compared with other antiphos‐

[15] Smith G.C.S., Crossley J.A., Aitken D.A., Pell J.P., Cameron A.D., Connor J.M. & Dob‐ bie R. First-trimester placentation and the risk of antepartum stillbirth. JAMA, Vol.

[16] Oshiro B.T., Silver R.M., Scott J.R., Yu H. & Branch D.W. Antiphospholipid antibod‐ ies and fetal death. Obstet Gynecol, Vol. 87, No. 4, (Apr 1996), pp. 489–493.

[17] Clark E.A., Silver R.M. & Branch D.W. Do antiphospholipid antibodies cause pree‐ clampsia and HELLP syndrome? Curr Rheumatol Rep, Vol. 9, No. 3, (Jun 2007), pp.

[18] Vora S., Shetty S., Salvi V., SatoskarP. & Ghosh K. Thrombophilia and unexplained loss in Indian patients. Natl Med J India, Vol. 21, No. 3, (Jun 2008), pp. 116-119.

pholipid antibodies. Fertil Steril, Vol. 66, No. 4, (Oct 1996), pp. 540-546.

[14] Silver R.M. Fetal death. Obstet Gynecol, Vol. 109, No. 1, (Jan 2007), pp. 153-167.

drome. J Clin Invest, Vol. 112, No. 11, (Dec 2003), pp. 1644–1654.

Haemost, Vol. 4, No.2, (Feb 2006), pp. 295-306.

No. 8716, (Sep 1990), pp. 673-675.

No. 8, (Aug 1995), pp. 2001-2005.

292, No. 18, (Nov 2004), pp. 2249–2254.

219-225.

2, (Jan 2002), pp. 211–220.

(Jan 2005), pp. 485–490.

## **Author details**

Chiara Tersigni, Silvia D'Ippolito and Nicoletta Di Simone

Department of Obstetrics and Gynaecology, Università Cattolica del Sacro Cuore, Rome, Italy

## **References**


[7] Holers V.M., Girardi G., Mo L., Guthridge J.M., Molina H., Pierangeli S.S., Espinola R., Xiaowei L.E., Mao D., Vialpando C.G. & Salmon J.E. Complement C3 activation is required for antiphospholipid antibody-induced fetal loss. J Exp Med, Vol. 195, No. 2, (Jan 2002), pp. 211–220.

to treat more selectively the aPL antibodies-induced placental damage and to ameliorate the reproductive performance of women with APS. Studies on humans are required to verify the

Department of Obstetrics and Gynaecology, Università Cattolica del Sacro Cuore, Rome,

[1] Wilson W.A., Gharavi A.E., Koike T., Lockshin M.D., Branch D.W., Piette J.C., Brey R., Derksen R., Harris E.N., Hughes G.R., Triplett D.A. & Khamashta M.A. Interna‐ tional consensus statement on preliminary classification criteria for definite antiphos‐ pholipid syndrome: report of an international workshop. Arthritis Rheum, Vol. 42,

[2] Miyakis S., Lockshin M.D., Atsumi T., Branch D.W., Brey R.L., Cervera R., Derksen R.H., DE Groot P.G., Koike T., Meroni P.L., Reber G., Shoenfeld Y., Tincani A., Vla‐ choyiannopoulos P.G. & Krilis S.A. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb

[3] Woodhams B.J., Candotti G., Shaw R. & Kernoff P.B. Changes in coagulation and fibrinolysis during pregnancy: evidence of activation of coagulation preceding spon‐

[4] Chamley L.W. Action of anticardiolipin andantibodies to beta2-glycoprotein-I on trophoblast proliferation as a mechanism for fetal death. Lancet, Vol. 352, No. 9133,

[5] Franklin R.D. & Kutteh W.H. Effects of unfractionated and low molecular weight heparin on antiphospholipid antibody binding in vitro. Obstet Gynecol, Vol. 101, No.

[6] Erkan A., Harrison M.J., Levy R., Peterson M., Petri M., Sammaritano L., Unalp-Ari‐ da A., Vilela V., Yazici Y. & Lockshin M.D. Aspirin for primary thrombosis preven‐ tion in the antiphospholipid syndrome: a randomized, double-blind, placebocontrolled trial in asymptomatic antiphospholipid antibody-positive individuals.

taneous abortion. Thromb Res, Vol. 55, No. 1, (Jul 1989), pp. 99-107.

Arthritis Rheum, Vol. 56, No. 7, (Jul. 2007), pp. 2382-2391.

safety profile and effectiveness of new therapies proposed.

Chiara Tersigni, Silvia D'Ippolito and Nicoletta Di Simone

No. 7, (Jul 1999), pp. 1309–1311.

(Sep 1998), pp. 1037-1038.

3, (Mar 2003), pp 455–462.

Haemost, Vol. 4, No.2, (Feb 2006), pp. 295-306.

**Author details**

94 Pregnancy Thrombophilia - The Unsuspected Risk

Italy

**References**


[19] Galli M., Luciani D., Bertolini G. & Barbui T. Anti-beta 2-glycoprotein I, antipro‐ thrombin antibodies, and the risk of thrombosis in the antiphospholipid syndrome. Blood, 2003, Vol. 102, No. 8, (Oct 2003), pp. 2717-2723.

[30] Ruiz-Irastorza G., Crowther M., Branch W. & Khamashta M.A. Antiphospholipid

Antiphospholipid Antibodies Syndrome and Reproductive Failures: New Therapeutic Trends Beyond…

http://dx.doi.org/10.5772/56862

97

[31] Peaceman, A.M. & Rehnberg, K.A. The effect of immunoglobulin G fractions from patients with lupus anticoagulant on placental prostacyclin and thromboxane pro‐

[32] Nayar R. & Lage J.M. Placental changes in a first trimester missed abortion in mater‐ nal systemic lupus erythematosus with antiphospholipid syndrome; a case report and review of the literature. Hum Pathol, Vol. 27, No. 2, (Feb 1996), pp. 201–206. [33] Rand, J.H., Wu X.X., Guller S., Gil J., Guha A., Scher J. & Lockwood C.J. Reduction of annexin-V (placental anticoagulant protein-I) on placental villi of women with anti‐ phospholipid antibodies and recurrent spontaneous abortion. Am J Obstet Gynecol,

[34] Horbach D.A., van Oort E., Lisman T., Meijers J.C., Derksen R.H. & de Groot P.G. Be‐ ta2-glycoprotein I is proteolytically cleaved in vivo upon activation of fibrinolysis.

[35] Derksen R.H., Khamasthta M.A. & Branch D.W. Management of the obstetric anti‐ phospholipid syndrome. Arthritis Rheum, Vol., No. 4, (Apr 2004), pp. 1028–1039. [36] Out H.J., Kooijman C.D., Bruinse H.W. & Derksen R.H. Histopathological finding from patient with intrauterine fetal death and antiphospholipid antibodies. Eur J Ob‐

[37] Park A.L. (2006). Placental pathology in antiphospholipid syndrome, In: Hughes'

[38] Meroni P.L., Tedesco F., Locati M., Vecchi A., Di Simone N., Acaia B., Pierangeli S.S. & Borghi M.O. Anti-phospholipid antibody mediated fetal loss: still an open ques‐ tion from a pathogenic point of view. Lupus, Vol. 19, No.4, (Apr 2010), pp. 453-456.

[39] Di Simone N., Meroni P.L., de Papa N., Raschi E., Caliandro D., De Carolis C.S., Kha‐ mashta M.A., Atsumi T., Hughes G.R., Balestrieri G., Tincani A., Casali P. & Caruso A. Antiphospholipid antibodies affect trophoblast gonadotropin secretion and inva‐ siveness by binding directly and through adhered beta2-glycoprotein I. Arthritis

[40] Katsuragawa H., Kanzaki H., Inoue T., Hirano T., Mori T. & Rote N.S. Monoclonal antibody against phosphatidylserine inhibits in vitro human trophoblastic hormone

[41] Rote N.S., Vogt E., DeVere G., Obringer A.R. & Ng A.K. The role of placental tropho‐ blast in the pathophysiology of the antiphospholipid antibody syndrome. Am J Re‐

production and invasion. Biol Reprod, Vol. 56, No. 1, (Jan 1997), pp. 50–58.

Syndrome, Khamashta M. A. pp. 362–374, Springer-Verlag, London.

duction. Am J Obstet Gynecol, Vol. 169, No. 6, (Dec 1993), pp. 1403–1406.

syndrome. Lancet, Vol. 76, No. 9751, (Oct 2010), pp. 1498-1509.

Vol. 171, No. 6, (Dec 1994), pp. 1566–1572.

Thromb Haemost, Vol. 81, No. 1, (Jan 1999), pp. 87-95.

stet Gynecol, Vol. 41, No. 3, (Oct 1991), pp. 179-186.

Rheum, Vol. 43, No. 1, (Jan 2000), pp. 140-150.

prod Immunol, Vol. 39, No. 2, (Feb 1998), pp. 125-136.


[30] Ruiz-Irastorza G., Crowther M., Branch W. & Khamashta M.A. Antiphospholipid syndrome. Lancet, Vol. 76, No. 9751, (Oct 2010), pp. 1498-1509.

[19] Galli M., Luciani D., Bertolini G. & Barbui T. Anti-beta 2-glycoprotein I, antipro‐ thrombin antibodies, and the risk of thrombosis in the antiphospholipid syndrome.

[20] Rand, J.H., Wu X.X., Quinn A.S. & Taatjes D.J. The annexin A5-mediated pathogenic mechanism in the antiphospholipid syndrome: role in pregnancy losses and throm‐

[21] Pierangeli S.S., Chen P.P., Raschi E., Scurati S., Grossi C., Borghi M.O., Palomo I., Harris E.N. & Meroni P.L. Antiphospholipid antibodies and the antiphospholipid syndrome: pathogenic mechanisms. Semin Thromb Hemost, Vol. 34, No.3, (Apr

[22] Pierangeli S.S., Chen P.P. & González E.B. Antiphospholipid antibodies and the anti‐ phospholipid syndrome: an update on treatment and pathogenic mechanisms. Curr

[23] Lopez-Pedrera C., Cuadrado M.J., Herández V., Buendïa P., Aguirre M.A., Barbarroja N., Torres L.A., Villalba J.M., Velasco F. & Khamashta M. Proteomic analysis in mon‐ ocytes of antiphospholipid syndrome patients: Deregulation of proteins related to the development of thrombosis. Arthritis Rheum, Vol. 58, No. 9, (Sep 2008), pp.

[24] Montiel-Manzano G., Romay-Penabad Z., Papalardo de Martínez E., Meillon-García L.A., García-Latorre E., Reyes-Maldonado E. & Pierangeli S.S. In vivo effects of an in‐ hibitor of nuclear factor-kappa B on thrombogenic properties of antiphospholipid an‐

[25] Vega-Ostertag M., Casper K., Swerlick R., Ferrara D., Harris E.N. & Pierangeli SS. (2005). Involvement of p38 MAPK in the up-regulation of tissue factor on endothelial cells by antiphospholipid antibodies. Arthritis Rheum, Vol. 52, No. 5, (May 2005), pp.

[26] de Groot P.G. & Derksen R.H. Pathophysiology of the antiphospholipid syndrome. J

[27] Pierangeli S.S., Girardi G., Vega-Ostertag M., Liu X., Espinola R.G. & Salmon J. Re‐ quirement of activation of complement C3 and C5 for antiphospholipid antibody mediated thrombophilia. Arthritis Rheum, Vol. 52, No.7, (Jul 2005), pp. 2120-2124. [28] Girardi G., Redecha P. & Salmon J.E. Heparin prevents antiphospholipid antibodyinduced fetal loss by inhibiting complement activation. Nat Med, Vol. 10, No.11,

[29] Meroni P.L., Borghi M.O., Raschi E., Ventura D., Sarzi Puttini P.C., Atzeni F., Lonati L., Parati G., Tincani A., Mari D. & Tedesco F. Inflammatory response and the endo‐

Blood, 2003, Vol. 102, No. 8, (Oct 2003), pp. 2717-2723.

bosis. Lupus, Vol. 19, No. 4, (Apr 2010), pp. 460–469.

Opin Hematol, Vol. 13, No. 5, (Sep 2006), pp. 366-375.

tibodies. Ann N Y Acad Sci, No. 1108, (Jun 2007), pp. 540-553.

Thromb Haemost, Vol. 3, No. 8, (Aug 2005), pp. 1854-1860.

thelium. Thromb Res, Vol. 114, No.5-6, (2004), pp. 329-334.

2008), pp. 236-250.

96 Pregnancy Thrombophilia - The Unsuspected Risk

2835–2844.

1545-1554.

(Nov 2004), pp. 1222-1226.


[42] Wang S.X., Sun Y.T. & Sui S.F. Membrane-induced conformational change in human apolipoprotein. H Biochem J, Vol. 348, (May 2000), pp. 103–106.

[53] Leach R.E., Romero R., Kim Y.M., Chaiworapongsa T., Kilburn B., Das S.K., Dey S.K., Johnson A., Qureshi F., Jacques S. & Armant D.R. Pre-eclampsia and expression of heparin-binding EGF-like growth factor. Lancet, Vol. 360, No. 9341, (Oct 2002), pp.

Antiphospholipid Antibodies Syndrome and Reproductive Failures: New Therapeutic Trends Beyond…

http://dx.doi.org/10.5772/56862

99

[54] Di Simone N., Marana R., Castellani R., Di Nicuolo F., D'Alessio M.C., Raschi E., Bor‐ ghi M.O., Chen P.P., Sanguinetti M., Caruso A. & Meroni P.L. Decreased expression of heparin-binding epidermal growth factor-like growth factor as a newly identified pathogenic mechanism of antiphospholipid-mediated defective placentation. Arthri‐

[55] Di Simone N., Di Nicuolo F., D'Ippolito S., Castellani R., Tersigni C., Caruso A., Mer‐ oni P. & Marana R. Antiphospholipid antibodies affect human endometrial angio‐

[56] D'Ippolito S., Marana R., Di Nicuolo F., Castellani R., Veglia M., Stinson J., Scambia G. & Di Simone N. Effect of Low Molecular Weight Heparins (LMWHs) on antiphos‐ pholipid Antibodies (aPL)-mediated inhibition of endometrial angiogenesis. PLoS

[57] Kolyada A., Lee C.J., De Biasio A. & and Beglova N. A novel dimeric inhibitor target‐ ing Beta2GPI in Beta2GPI/antibody complexes implicated in antiphospholipid syn‐

[58] Ostertag M.V., Liu X., Henderson V. & Pierangeli S.S. A peptide that mimics the Vth region of beta–2–glycoprotein I reverses antiphospholipid–mediated thrombosis in

[59] Martinez de la Torre Y., Pregnolato F., D'Amelio F., Grossi C., Di Simone N., Pasqua‐ lini F., Nebuloni M., Chen P., Pierangeli S., Bassani N., Ambrogi F., Borghi M.O., Vec‐ chi A., Locati M. & Meroni P.L. Anti–phospholipid induced murine fetal loss: novel protective effect of a peptide targeting the β2 glycoprotein I phospholipid–binding site. Implications for human fetal loss. J Autoimmun, Vol. 38, No. 2-3, (May 2012),

[60] Gharavi A.E., Pierangeli S.S., Espinola R.G., Liu.X., Colden-Stanfield M. & Harris E.N. Antiphospholipid antibodies induced in mice by immunization with a cytome‐ galovirus–derived peptide cause thrombosis and activation of endothelial cells in

[61] Gharavi A.E., Vega–Ostertag M., Espinola R.G., Liu X., Cole L., Cox N.T., Romagnoli P., Labat K. & Pierangeli S.S.. Intrauterine fetal death in mice caused by cytomegalo‐ virus derived peptide induced aPL antibodies. Lupus, Vol. 13, No. 1, (2004), pp. 17–

[62] Del Papa N., Sheng Y.H., Raschi E., Kandiah D.A., Khamashta M.A., Atsumi T., Hughes G.R., Ichikawa K., Koike T., Balestrieri G., Krilis S.A. & Meroni P.L. Human beta 2–glycoprotein I binds to endothelial cells through a cluster of lysine residues

vivo. Arthritis Rheum, Vol. 46, No. 2, (Feb. 2002), pp. 545–552.

tis Rheum, Vol. 62, No. 5, (May 2010), pp. 1504-1512.

drome. PLoS One, Vol. 5, No. 12, (Dec 2010), e15345.

mice. Lupus, Vol. 15, No. 6, (2006), pp. 358–365.

One, Vol. 7, No. 1, (Jan 2012), e29660.

genesis. Biol Reprod, Vol. 83, No. 2, (Aug 2010), pp. 212-219.

1215–1219.

pp. 209–215.

23.


[53] Leach R.E., Romero R., Kim Y.M., Chaiworapongsa T., Kilburn B., Das S.K., Dey S.K., Johnson A., Qureshi F., Jacques S. & Armant D.R. Pre-eclampsia and expression of heparin-binding EGF-like growth factor. Lancet, Vol. 360, No. 9341, (Oct 2002), pp. 1215–1219.

[42] Wang S.X., Sun Y.T. & Sui S.F. Membrane-induced conformational change in human

[43] Lyden T.W., Vogt E., Ng A.K., Johnson P.M. & Rote N.S. Monoclonal antiphospholi‐ pid antibody reactivity against human placental trophoblast. J Reprod Immunol, Vol.

[44] Guerin J., Sheng Y., Reddel S., Iverson G.M., Chapman M.G. & Krilis S.A. Heparin inhibits the binding of beta 2-glycoprotein I to phospholipids and promotes the plas‐ min-mediated inactivation of this blood protein. Elucidation of the consequences of the two biological events in patients with the anti-phospholipid syndrome. J Biol

[45] Di Simone N., Ferrazzani S., Castellani R., De Carolis S., Mancuso S. & Caruso A. Heparin and low dose aspirin restore placental human chorionic gonadotrophin se‐ cretion abolished by antiphospholipid antibody-containing sera. Hum Reprod, Vol.

[46] Di Simone N., Caliandro D., Castellani R., Ferrazzani S., De Carolis S. & Caruso A. Low-molecular weight heparin restores in-vitro trophoblast invasiveness and differ‐ entiation in presence of immunoglobulin G fractions obtained from patients with an‐ tiphospholipid syndrome. Hum Reprod, Vol. 14, No. 2, (Feb1999), pp. 489-495.

[47] Raab G. & Klagsbrun M. Heparin binding EGF growth factor. Biochim Biophys Acta,

[48] Iwamoto R. & Mekada E. Heparin-binding EGF-like growth factor: a juxtacrine growth factor. Cytokine Growth Factor Rev, Vol. 11, No. 4, (Dec 2000), pp. 335-344.

[49] Martin K.L., Barlow D.H. & Sargent I.L. Heparin-binding epidermal growth factor significantly improves human blastocyst development and hatching in serum-free

[50] Wang J., Mayernik L., Schultz J.F. & Armant D.R. Acceleration of trophoblast differ‐ entiation by heparinbinding EGF-like growth factor is dependent on the stage-specif‐ ic activation of calcium influx by ErbB receptors in developing mouse blastocysts.

[51] Paria B.C., Ma W., Tan J., Raja S., Das S.K., Dey S.K. & Hogan B.L. Cellular and mo‐ lecular responses of the uterus to embryo implantation can be elicited by locally ap‐ plied growth factors. Proc Natl Acad Sci U S A, Vol. 98, No. 3, (Jan 2001), pp.

[52] Leach R.E., Khalifa R., Ramirez N.D., Das S.K., Wang J., Dey S.K., Romero R. & Arm‐ ant D.R. Multiple roles for heparin-binding epidermal growth factor-like growth fac‐ tor are suggested by its cell-specific expression during the human endometrial cycle and early placentation. J Clin Endocrinol Metab, Vol. 84, No. 9, (Sep 1999), pp. 3355–

medium. Hum Reprod, Vol. 13, No. 6, (Jun 1998), pp. 1645-1652.

Development, Vol. 127, No. 1, (Jan 2000), pp. 33–44.

1047-1052.

63.

apolipoprotein. H Biochem J, Vol. 348, (May 2000), pp. 103–106.

22, No. 1, (Jun 1992), pp. 1-14.

98 Pregnancy Thrombophilia - The Unsuspected Risk

Chem, Vol. 277, No. 4, (Jan 2002), pp.2644-2649.

12, No. 9, (Sep 1997), pp. 2061-2065.

Vol. 1333, No. 3, (Dec 1997), pp. 179–99.


that are critical for anionic phospholipid binding and offers epitopes for anti–beta 2– glycoprotein I antibodies. J Immunol, Vol. 160, No. 11, (Jun 1998), pp. 5572–5578.

[73] Rops A.L., van der Vlag J., Lensen F.J., Wijnhoven T.J., van den Heuvel L.P, van Kup‐ pevelt T.H. & Berden J.H. Heparan sulphate proteoglycans in glomerular inflamma‐

Antiphospholipid Antibodies Syndrome and Reproductive Failures: New Therapeutic Trends Beyond…

http://dx.doi.org/10.5772/56862

101

[74] Mollnes T.E., Brekke O.L., Fung M., Fure H., Christiansen D., Berseth G., Videm V., Lappegard K.T., Kökl J. &Lambris J.D. Essential role of the C5a receptor in E coli-in‐ duced oxidative burst and phagocytosis revealed by a novel lepirudin-based human whole blood model of inflammation. Blood, Vol. 100, No. 5, (Sep 2002), pp.

[75] Hochart H., Jenkins P.V., Smith O.P. & White B. Low-molecular weight and unfrac‐ tionated heparins induce a downregulation of inflammation: decreased levels of proinflammatory cytokines and nuclear factor-kappaB in LPS-stimulated human

[76] Berman J., Girardi G. & Salmon J.E. TNF-alpha is a critical effector and a target for therapy in antiphospholipid antibody-induced pregnancy loss. J Immunol, Vol. 174,

[77] Carp H.J.A. Intravenous Immunoglobulin: Effect on Infertility and Recurrent Preg‐

[78] Bakimer R., Gilburd B., Zurgil N. & Shoenfeld Y. The effect of intravenous gamma‐ globulin on the induction of experimental antiphospholipid syndrome. Clin Immu‐

[79] Branch D.W., Peaceman A.M., Druzin M., Silver R.K., El-Sayed Y., Silver R.M., Esplin M.S., Spinnato J. & Harger J. A multicenter, placebo-controlled pilot study of intrave‐ nous immune globulin treatment of antiphospholipid syndrome during pregnancy. The Pregnancy Loss Study Group. Am J Obstet Gynecol, Vol. 182, No. 1, (Jan 2000),

[80] Blank M., Anafi L., Zandman-Goddard G., Krause I., Goldman S., Shalev E., Cervera R., Font J., Fridkin M., Thiesen H.J. & Shoenfeld Y. The efficacy of specific IVIG antiidiotypic antibodies in antiphospholipid syndrome (APS): trophoblast invasiveness and APS animal model. International Immunology, Vol. 19, No. 7, (Jul 2007), pp.

[81] Camerer E., Huang W. & Coughlin S.R. Tissue factor and factor X-dependent activa‐ tion of ptotease-activated receptor 2 by factor VIIa. Proc Natl Acad Sci USA, Vol. 97,

[82] Ruf W., Dorfleutner A. & Riewald M. Specificity of coagulation factor signaling. J

[83] Mueller B.M., Reisfeld R.A., Edgington T.S. & Ruf W. Expression of tissue factor by melanoma cells promotes efficient hematogenous metastasis. Proc Natl Acad Sci

monocytes. Br J Haematol, Vol. 133, No. 1, (Apr 2006), pp. 62-67.

nancy Loss. IMAJ, Vol. 12, No. 9, (Dec 2007), pp. 877–880.

nol Immunopathol, Vol. 69, No. 1, (Oct 1993), pp. 97–102.

Thromb Haemost, Vol. 1, No. 7, (Jul 2003), pp. 1495–1503.

tion. Kidney Int, Vol. 65, No. 3, (Mar 2004), pp. 768-785.

1869-1877.

pp. 122–127.

857–865.

No. 10, (May 2000), pp. 5255-5260.

USA, Vol. 89, No. 24, (Dec1992), pp. 1–6.

No. 1, (Jan 2005), pp. 485-490.


[73] Rops A.L., van der Vlag J., Lensen F.J., Wijnhoven T.J., van den Heuvel L.P, van Kup‐ pevelt T.H. & Berden J.H. Heparan sulphate proteoglycans in glomerular inflamma‐ tion. Kidney Int, Vol. 65, No. 3, (Mar 2004), pp. 768-785.

that are critical for anionic phospholipid binding and offers epitopes for anti–beta 2– glycoprotein I antibodies. J Immunol, Vol. 160, No. 11, (Jun 1998), pp. 5572–5578.

[63] Di Simone N., Raschi E., Testoni C., Castellani R., D'Asta M., Shi T., Krilis S.A., Caru‐ so A. & Meroni P.L. Pathogenic role of anti–ß2–glycoprotein I antibodies in antiphos‐ pholipid associated fetal loss: characterization of ß2–glycoprotein I binding to trophoblast cells and functional effects of anti–ß2–glycoprotein I antibodies in vitro.

[64] Peaceman A.M & Rehnberg K.A. The effect of immunoglobulin G fractions from pa‐ tients with lupus anticoagulant on placental prostacyclin and thromboxane produc‐

[65] Nayar R. & Lage J.M. Placental changes in a first trimester missed abortion in mater‐ nal systemic lupus erythematosus with antiphospholipid syndrome; a case report and review of the literature. Hum Pathol, Vol. 27, No. 2, (Feb 1996), pp. 201–206.

[66] Di Simone N., D'Ippolito S., Marana R., Di Nicuolo F., Castellani R., Pierangeli S.S., Chen P.P., Tersigni C., Scambia G. & Meroni P.L. Antiphospholipid Antibodies Af‐ fect Human Endometrial Angiogenesis: protective effect of a synthetic peptide (TIFI) mimicking the phospholipid binding site of β2glycoprotein I. Am J Reprod Immunol,

[67] Chaouat G. The Th1/Th2 paradigm: still important in pregnancy? Semin Immunopa‐

[68] Thurman, J.M., Kraus D.M., Girardi G., Hourcade D., Kang H.J., Royer P.A., Mitchell L.M., Giclas P.C., Salmon J., Gilkeson G. & Holers V.M. A novel inhibitor of the alter‐ native complement pathway prevents antiphospholipid antibody-induced pregnan‐

[69] Girardi G., Yarilin D., Thurman J.M., Holers V.M. & Salmon J.E. Complement activa‐ tion induces dysregulation of angiogenic factors and causes fetal rejection and

[70] Friedrichs G.S., Kilgore K.S., Manley P.J., Gralinsky M.R. & Lucchesi B.R. Effect of heparin and N-acetyl heparin on ischemia/reperfusion-induced alterations in myo‐ cardial function in the rabbit isolated heart. Circ Res, Vol. 75, No. 4, (Oct 1994), pp.

[71] Koenig A., Norgard-Sumnicht K., Lindhardt R. & Varki A. Differential interactions of heparin and heparan sulfate glycosaminoglycans with the selectins. Implications for the use of unfractionated and low molecular weight heparins as therapeutic agents. J

[72] Wang L., Brown J.R., Varki A. & Esko J.D. Heparin's anti-inflammatory effects re‐ quire glucosamine 6-O-sulfation and are mediated by blockade of L- and P- selectins.

growth restriction. J Exp Med, Vol. 203, No. 9, (Sep 2006), pp. 2165–2175.

cy loss in mice. Mol Immunol, Vol. 42, No. 1, (Jan 2005), pp. 87–97.

tion. Am J Obstet Gynecol, Vol. 169, No. 6, (Dec 1993), pp. 1403–1406.

Ann Rheum Dis, Vol. 64, No. 3., (Mar 2005), pp. 462–467.

(May 2013) (in press).

100 Pregnancy Thrombophilia - The Unsuspected Risk

701-710.

thol, Vol. 29, No. 2, (Jun 2007), pp. 95–113.

Clin Invest, Vol. 101, No. 4, (Feb 1998), pp. 877-889.

J Clin Invest, Vol. 110, No. 1, (Jul 2002), pp. 127-136.


[84] Cuadrado M.J., López-Pedrera C., Khamashta M.A. Camps M.T., Tinahones F., Torres A., Hughes G.R. & Velasco F. Thrombosis in primary antiphospholipid syn‐ drome: a pivotal role for monocyte tissue factor expression. Arthritis Rheum, Vol. 40, No. 5 (May 1997), pp. 834–841.

phospholipid antibodymediated thrombosis and endothelial cell activation. J

Antiphospholipid Antibodies Syndrome and Reproductive Failures: New Therapeutic Trends Beyond…

http://dx.doi.org/10.5772/56862

103

[95] Ritis K., Doumas M., Mastellos D., Micheli A., Glaglis S., Magotti P., Rafail S., Karta‐ lis G., Sideras P. & Lambris J.D. A novel C5a receptor-tissue factor cross-talk in neu‐ trophils links innate immunity to coagulation pathways. J Immunol, Vol. 177, No. 7,

[96] Redecha P., Tilley R., Tencati M., Samon J.E., Kirchhofer D., Mackman N. & Girardi G. Tissue factor: a link between C5a and neutrophil activation in antiphospholipid antibody induced fetal injury. Blood, Vol. 110, No. 7, (Oct 2007), pp. 2423–2431. [97] Redecha P., Franzke C.W., Ruf W., Mackman N. & Girardi G. Neutrophil activation by the tissue factor/Factor VIIa/PAR2 axis mediates fetal death in a mouse model of antiphospholipid syndrome. J Clin Invest, Vol. 118, No. 10, (Oct 2008), pp. 3453–3461.

[98] Kunieda Y., Nakagawa K., Nishimura H., Kato H., Ukimura N., Yano S., Kawano H., Kimura S., Nakagawa M. &Tsuji H. HMG CoA reductase inhibitor suppresses the ex‐ pression of tissue factor and plasminogen activator inhibitor-1 induced by angioten‐ sin II in cultured rat aortic endothelial cells. Thromb Res, Vol. 110, No. 4, (Jun 2003),

[99] Girardi G. Pravastatin prevents miscarriages in antiphospholipid antibody-treated

[100] Pollack P.S., Shields K.E., Burnett D.M., Osborne M.J., Cunningham M.L. & Stepa‐ navage M.E. Pregnancy outcomes after maternal exposure to simvastatin and lova‐ statin. Birth Defects Res A Clin Mol Teratol, Vol. 73, No. 11, (Nov 2005), pp.888–896.

[101] Edison R.J. & Muenke M. Mechanistic and epidemiologic considerations in the evalu‐ ation of adverse birth outcomes following gestational exposure to statins. Am J Med

[102] Mulla M.J., Brosens J.J., Chamley L.W., Giles I., Pericleous C., Rahman A., Joyce S.K., Panda B., Paidas M.J. & Abrahams V.M. Antiphospholipid antibodies induce a proinflammatory response in first trimester trophoblast via the TLR4/MyD88 pathway.

mice. Journal Reprod Immunol, Vol. 82, No. 2, (Nov. 2009), pp. 126–131.

Genet A, Vol. 131, No. 3, (Dec 2004), pp. 230–231.

Am J Reprod Immunol, Vol. 62, No. 2, (Aug 2009), pp. 96-111.

Thromb Haemost, Vol. 5, No. 9, (Sep 2007), pp.1828–1834.

(Oct 2006), pp. 4794–4802.

pp. 227–234.


phospholipid antibodymediated thrombosis and endothelial cell activation. J Thromb Haemost, Vol. 5, No. 9, (Sep 2007), pp.1828–1834.

[95] Ritis K., Doumas M., Mastellos D., Micheli A., Glaglis S., Magotti P., Rafail S., Karta‐ lis G., Sideras P. & Lambris J.D. A novel C5a receptor-tissue factor cross-talk in neu‐ trophils links innate immunity to coagulation pathways. J Immunol, Vol. 177, No. 7, (Oct 2006), pp. 4794–4802.

[84] Cuadrado M.J., López-Pedrera C., Khamashta M.A. Camps M.T., Tinahones F., Torres A., Hughes G.R. & Velasco F. Thrombosis in primary antiphospholipid syn‐ drome: a pivotal role for monocyte tissue factor expression. Arthritis Rheum, Vol. 40,

[85] Dobado-Berrios P.M., Lopez-Pedrera C., Velasco F., Aguirre M.A., Torres A. & Cua‐ drado M.J. Increased levels of tissue factor mRNA in mononuclear blood cells of pa‐ tients with primary antiphospholipid syndrome. Thromb Haemost, Vol. 82, No. 6,

[86] Reverter J.C., Tassies D., Font J., Monteagudo J., Escolar J., Ingelmo M. & Ordinas A. Hypercoagulable state in patients with antiphospholipid syndrome is related to high induced tissue factor expression on monocytes and to low free protein S. Arterioscler

[87] Nojima J., Masuda Y., Iwatani Y., Suehisa E., Futsukaichi Y., Kuratsune H., Watanabe Y., Takano T., Hidaka Y., Kanakura Y. Tissue factor expression on monocytes in‐ duced by anti-phospholipid antibodies as a strong risk factor for thromboembolic complications in SLE patients. Biochem Biophys Res Commun, Vol. 365, No. 1 (Jan

[88] Amengual O., Atsumi T., Khamashta M.A. & Hughes G.R.V. The role of the tissue factor pathway in the hypercoagulable state in patients with the antiphospholipid

[89] Zhou H., Walberg A.S. & Roubey R.A.S. Characterization of monocyte tissue factor activity induced by IgG antiphospholipid antibodies and inhibition by dilazep.

[90] Roubey R.A., Pratt C.W., Buyon J.P. & Winfield J.B. Lupus anticoagulant activity of autoimmune antiphospholipid antibodies is dependent upon beta 2-glycoprotein I. J

[91] Vega-Ostertag M., Casper K., Swerlick R., Ferrara D., Harris E.N. & Pierangeli S.S. In‐ volvement of p38 MAPK in the upregulation of tissue factor on endothelial cells by antiphospholipid antibodies. Arthritis Rheum, Vol. 52, No. 5, (May 2005), pp. 1545–

[92] Lopez-Pedrera C., Buendia P., Barbarroja N., Siendones E., Velasco F. & Cuadrado M.J. Antiphospholipid-mediated thrombosis: interplay between anticardiolipin anti‐ bodies and vascular cells. Clin Appl Thromb Hemost, Vol. 12, No. 1, (Jan 2006), pp.

[93] Kornberg A., Renaudineau Y., Blank M., Youinou P. & Sheffield Y. Anti-beta2-glyco‐ protein I antibodies and anti-endothelial cell antibodies induce tissue factor in endo‐

[94] Vega-Ostertag M.E., Ferrara D.E., Romay-Penabad Z., Liu X., Taylor W.R., Colden-Stanfield M. & Pierangeli S.S. Role of p38 mutagen-activated protein kinas in anti‐

syndrome. Thromb Haemost, Vol. 79, No. 2, (Feb 1998), pp. 276–281.

Blood, Vol. 104, No. 8, (Oct 2004), pp. 2353–2358.

Clin Invest, Vol. 90, No. 3, (Sep 1992), pp. 1100–1104.

thelial cells. Isr Med Assoc J, Vol. 2, (Jul 2000), pp.27–31.

Thromb Vasc Biol, Vol. 16, No. 11, (Nov 1996), pp. 1319–1326.

No. 5 (May 1997), pp. 834–841.

102 Pregnancy Thrombophilia - The Unsuspected Risk

(Dec 1999), pp.1578–1582.

2008), pp. 195–200.

1554.

41–45.


**Chapter 6**

**Thrombophilia in Systemic Lupus Erythematosus: A**

**Outcomes**

**1. Introduction**

Patricia J. Dhar and Robert J. Sokol

http://dx.doi.org/10.5772/56902

Additional information is available at the end of the chapter

**Review of Multiple Mechanisms and Resultant Clinical**

Systemic lupus erythematosus, or SLE is a multisystem autoimmune disease that occurs predominantly in African American women of childbearing age, who generally have more severe disease. There are several multi-ethnic global lupus registries ongoing to collect better information on the epidemiology of SLE worldwide [1]. The annual incidence of SLE is 3 cases / 100,000 with prevalence rates reported up to 144/100,000 among the general population [1-2], 90% of SLE patients being female gender. African Americans and Hispanics as well as males with lupus, general ly have more severe diseases, particularly renal disease, with some studies also showing this association in Asians [1-2]. SLE is a thrombophilic state. Patients with SLErelated hypercoagulability can develop arterial and venous thrombosis as well as intrauterine fetal demise, such as miscarriages and stillbirths. Multiple mechanisms contribute to hyper‐ coagulability in SLE, including lupus specific factors such as antiphospholipid antibodies. These antibodies also contribute to cardiovascular and cerebrovascular disease in lupus. The inflammation in SLE can increase certain procoagulant factors which can tip the balance towards thrombosis. In addition, platelet hyperfunction in SLE promotes thrombogenesis and is particularly important in premature cardiovascular disease management in women with lupus. Thrombogenesis in SLE is best explained by the multiple-hit theory in which several procoagulant or anticoagulant effects occur, which additively can attain the critical overall effect needed to generate a blood clot. Thus, when assessing lupus patients for thrombosis or intrauterine fetal demise, a larger laboratory work up is needed to define the coagulation abnormalities in order to fine tune the most effective anticoagulation regimen as well as determine length of treatment. This chapter will briefly review the clinical syndromes associated with thrombophilic lupus related antibodies, with an emphasis on pregnancy loss,

> © 2013 Dhar and Sokol; licensee InTech. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

and reproduction in any medium, provided the original work is properly cited.

© 2013 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution,
